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2ABSTRACT
There is a general perception that biomedical research has not given the same attention to
the health problems of women that it has given to those of men, and that women may not
have beneﬁted from advances in medical diagnosis and therapy because of their lower rates
of participation in clinical studies. This paper explores the historical exclusion of women of
childbearing potential from clinical trials and the changes in policy and regulations that have
occurred. The recent shift from protectionist policies toward policies of access and inclusion
remains controversial. Arguments and rationales for and against including women in clinical
trials are described, and the empirical evidence of women’s participation in these trials is
analyzed. It appears that the current regulatory system, supported by federal policy, promotes
the inclusion of women in clinical trials, and the results of empirical studies indicate that women
are in fact being included. The beneﬁts of inclusion, balanced against the increased cost of
including women, reveal that the added cost of inclusion and subgroup diﬀerences analysis may
jeopardize the long-term goals of improving scientiﬁc knowledge and understanding the health
problems of all peoples. Alternatives to clinical trials are discussed as a means of producing
similar information at lower cost. The paper concludes with a brief discussion of the need to
change the popular perception that women are being neglected by clinical research to their
detriment, rather than changing the existing policy and regulatory system regarding their
inclusion in clinical trials.
INTRODUCTION
In the past two decades, a perception has grown that the nation’s clinical research enterprise has focused
more on the health problems of men than on those of women, particularly so in regard to clinical trials, and
that women have been denied access to advances in medical diagnosis and therapy as a result of being ex-
cluded from these trials.1 At the same time, there have been substantial changes in federal research policies
regarding the inclusion of women in clinical trials. The prevailing perception that women have been system-
atically excluded from clinical research to their detriment is highly controversial, igniting conﬂict between
those who hold the perception and those who do not, and between concerns about protecting women from
the risks of participation in research and about their access to its potential beneﬁts.
1A.C. Mastroianni, R. Faden, and D. Federman, eds., Women and Health Research: Ethical and Legal Issues of Including
Women in Clinical Studies, Volume 1 (Washington, D.C.: National Academy Press, 1994).
3This paper explores the participation of women of childbearing potential in clinical trials, the controversy sur-
rounding their participation, and the changes in federal regulations and policies regarding their involvement
in an attempt to explain the prevailing perception of exclusion and illuminate the reality of the situation.
Most controversial in the area of women’s participation in clinical trials is the participation of women of
childbearing potential, rather than pregnant women, in drug trials for diseases that aﬀect both men and
women, rather than conditions unique to women; the exclusion of pregnant women from trials and the ex-
clusion of women from trials for male-only diseases seems more justiﬁed even to the strongest advocates for
women’s health research.2 Thus, this paper focuses on these issues.
Part I describes the historical evolution of current policy and regulations regarding the participation of
women of childbearing potential in clinical drug trials. Part II presents the arguments and rationales for
and against the inclusion of this subgroup in clinical trials and the analysis of gender diﬀerences in drug
eﬀectiveness and response. Part III discusses the existing empirical evidence on women’s participation in
trials. Part IV is an analysis of current policy, regulations, and arguments, and concludes that while current
policy and regulations support and promote the inclusion of women in clinical trials, requiring the inclusion
of women in all clinical trials may in fact jeopardize, rather than beneﬁt, women’s health care due to the
expense of subgroup analysis. Alternatives to clinical trials are discussed that can enhance the understand-
ing of women’s health at lower cost and without jeopardizing their well-being. The paper concludes with a
discussion of how the prevailing perception that clinical research is tilted in favor of men has aﬀected current
policy and how women’s health care can best be served by changing this perception to reﬂect the current
state of women’s participation in clinical trials.
2R.B. Merkatz. 1993. “Women in Clinical Trials: An Introduction,” Food and Drug Law Journal 48(2): 161-6.
45PART I: Women’s Participation in Clinical Trials: Historical Background
Policy development in the area of protection of human research subjects began in 1949 with the issuance of the
Nuremberg Code, which outlined standards for the judgment of ﬂagrantly abusive human experimentation
conducted by the Nazis during World War II. The Code articulated ten basic principles concerning moral,
ethical, and legal requirements of research involving human subjects, including the provision that research
subjects must have the legal capacity to give consent, the ability to exercise free power of choice, and
suﬃcient knowledge and comprehension to be able to make an informed decision. The Code also dictated
that experiments involving human subjects should yield useful results that cannot be achieved by other
methods, avoid unnecessary suﬀering and injury, assure that risk does not exceed importance, and be done
by scientiﬁcally qualiﬁed persons with adequate facilities for subject protection. The Code further stipulated
that human subjects be at liberty to withdraw from the study at any time and that the scientist be prepared
to terminate the experiment if continuation was likely to result in injury, disability, or death to the subject.3
A. Protecting Human Subjects: The Evolution of Protectionist Regulation
In response to the Nuremberg Code, the Clinical Center of the National Institutes of Health, a research
hospital opened in 1953, formulated guidelines for clinical research. Titled “Group Considerations for Clin-
ical Research Procedures Deviating from Accepted Medical Practice or Involving Universal Hazards,” these
guidelines were the ﬁrst federal guidelines for human studies research and the ﬁrst oﬃcial statement requiring
committee review of human studies protocols.4
During the 1960s and 1970s, several unfortunate events indicated that serious problems remained with re-
3Women and Health Research: Ethical and Legal Issues of Including Women in Clinical Studies, Volume 1, supra note 1.
4Id. at 37.
6gard to the protection of human research subjects. Landmark research abuses, including those involving
elderly debilitated patients and African-Americans, signaled the need for the clariﬁcation and formalization
of existing guidelines for human subjects research. In 1963, it was discovered that a physician at the Jewish
Chronic Disease Hospital in Brooklyn, New York was experimentally injecting live cancer cells into elderly
debilitated patients without proper informed consent.5 Review proceedings indicated that the study had
not been presented to the hospital’s research committee and that several physicians responsible for the pa-
tient’s care had not been consulted before the injections were given. In 1965, Henry K. Beecher, a Harvard
anesthesiologist, gave a highly publicized speech that highlighted cases in the published literature of neglect
of the consent process in human subjects research.6 Then, in the early 1970s, the abuses of the infamous
Tuskegee Syphilis Study were revealed, adding fuel to arguments that human research subjects were not
being adequately protected by the existing guidelines and that more formal regulations were needed. This
observational study, begun in 1932, involved 400 African-American men many of whom were allowed to
remain untreated for the disease even after antibiotic treatment was widely available.7 Because the study
was initiated before the Nuremberg Code, it had not been subject to any ethical review, and funding for the
study had been renewed over the years in accordance with the recommendations of the investigators. Shortly
after these abuses were revealed, a congressional panel was convened to review the study’s history and to
recommend action by the federal government. Included in the panel’s ﬁnal report was the recommendation
that the Department of Health, Education, and Welfare’s (DHEW) standards regarding informed consent of
research subjects be clariﬁed and that an eﬀective enforcement mechanism be devised.8 On May 30, 1974,
existing guidelines for the protection of human research subjects ﬁnally took the shape of federal regula-
5Id. at 39.
6Id.
7J.H. Jones. Bad Blood: The Tuskegee Syphilis Experiment (New York: Free Press, 1981).
8U.S. Department of Health, Education, and Welfare (USDHEW). 1973. Final Report of the Tuskegee Syphilis Study Ad
Hoc Advisory Panel. Washington, D.C.
7tions.9 Promulgated by DHEW, the regulations established the institutional review board (IRB), a more
formal version of the research review committee, as one mechanism for the protection of human research
subjects. The responsibilities entrusted to the IRB included the reviewing of risk-beneﬁt ratios, conﬁdential-
ity protection, informed consent processes, and procedure for selection of subjects to ensure that selection
is equitable.10
In the 1960s and 1970s, as attention focused on the research abuses discovered at the Jewish Chronic Disease
Hospital and Tuskegee, health problems caused by the drugs thalidomide and diethylstilbestrol (DES) am-
pliﬁed public sentiment about the need for greater protection for fetuses from risks in science and medicine.
These concerns were ultimately translated into protective regulations directed toward women of childbearing
potential and pregnant women.
Thalidomide, approved for marketing in 1958 and approved for over-the-counter sale in twenty countries (not
including the United States) was used widely, primarily as a sedative and antidote for nausea in early preg-
nancy.11 Although marketing approval had been delayed in this country, many women received thalidomide
from “investigating” doctors who had been given the drug by the manufacturer.12 As thalidomide was being
widely distributed, physicians began to notice a startling increase in the number of children born with a rare
set of deformities, the most prominent of which were severe limb malformations. In 1962, when suﬃcient
statistical evidence had been obtained to establish a causal relationship between thalidomide and these de-
formities, nearly 8,000 children had been aﬀected.13 The thalidomide disaster was the result of inadequate
research standards, a failure of the drug’s manufacturer to acknowledge early evidence of side eﬀects, and
physicians’ uncritical acceptance of promotional claims.14 Yet, even though the disaster was not in fact the
9Women and Health Research: Ethical and Legal Issues of Including Women in Clinical Studies, Volume 1, supra note 1
at 39.
10Id.
11Id. at 40.
12Id.
13G.A. Christie. 1962. “Thalidomide and Congenital Abnormalities.” Lancet 2: 249.
14Women and Health Research: Ethical and Legal Issues of Including Women in Clinical Studies, Volume 1, supra note 1
8result of women’s participation in research, the experience nonetheless had a powerful emotional impact that
created an aversion to involving pregnant women and women of childbearing age in drug research.15 The
DES experience compounded this aversion.
In the 1940s and 1950s, enthusiastic physicians overlooked large, controlled clinical trials indicating that
DES, a synthetic hormone widely prescribed to prevent miscarriages, was ineﬀective, choosing instead to
focus on smaller studies showing that the drug was beneﬁcial.16 It was not until twenty years later, in
the late 1960s and early 1970s, that the side eﬀects of the drug became evident: the daughters of women
who had taken DES during pregnancy experienced a rare adenocarcinoma of the vagina.17 Public trust in
science and medicine was shaken once again, particularly because the drug continued to be prescribed even
after a controlled study in the 1950s disproved the drug’s clinical eﬃcacy, and a protectionist stance toward
including fertile women in drug trials was further entrenched.18 The response from the U.S. science establish-
ment was the creation of new legislation: the Kefauver-Harris amendments of 1962 mandated demonstration
that new drugs are eﬀective as well as safe before marketing and included a rigorous preapproval process
at the FDA.19 Again, even though the DES experiences were based on injuries incurred in the context of
medical practice rather than research, the substantial costs incurred by pharmaceutical companies through
DES-related litigation encouraged the practice of excluding pregnant and pregnable women from clinical
research.20
Thus, in 1975, Congress passed the National Research Act which called for the establishment of a National
Commission for the Protection of Human Subjects of Biomedical and Behavioral Research (National Com-
at 40.
15L.A. Eckenwiler. 1999. “Pursuing Reform in Clinical Research: Lessons from Women’s Experience,” Journal of Law,
Medicine, & Ethics 2(27): 1073-1105.
16Women and Health Research: Ethical and Legal Issues of Including Women in Clinical Studies, Volume 1, supra note 1
at 40.
17Id.
18L.A. Eckenwiler, supra note 15 at 1079.
19C. Levine. 1993. “Women as Research Subjects: New Priorities, New Questions.” In: Emerging Issues in Biomedical
Policy: An Annual Review, Volume 2, R.H. Blank and A.L. Bonnicksen, eds. (New York: Columbia University Press, 1993).
20Id.
9mission) to identify ethical principles and to develop guidelines for research involving human subjects.21 The
Commission, which operated between 1974 and 1978, developed guidelines in 1975 for research on fetuses
and pregnant women which were incorporated into the Department of Health and Human Service’s (DHHS)
regulations for research on human subjects. These federal regulations, still in eﬀect today, identify the lim-
ited conditions under which an institutional review board (IRB) may approve research on pregnant women
and fetuses.22 Subsequent regulations instituted to protect children and prisoners from research abuses have
grouped pregnant women in the category of “vulnerable populations,” a grouping that has been criticized
for implying that pregnant women are incapable of making responsible decisions for themselves and their
future oﬀspring.23
Although DHHD included restrictions on the inclusion of women of childbearing potential in earlier drafts
of the regulation concerning pregnant women, these references were eliminated from the ﬁnal regulation. In
1977, however, the Food and Drug Administration (FDA) issued a guideline for drug development entitled
“General Considerations for the Clinical Evaluation of Drugs” recommending that women of childbearing
potential be excluded from early phases of drug trials (Phase I and early Phase II) until reproductive tox-
icity studies were conducted and some evidence of eﬀectiveness had become available, thus formalizing the
consensus among clinical researchers in the wake of the DES experience.24 The recommended exclusion
was broadly applied to any “premenopausal female capable of becoming pregnant,” but explicitly did not
apply to women with life-threatening diseases.25 Although the FDA policy explicitly pertained only to the
exclusion of women of childbearing potential – deﬁned as such, regardless of whether they were pregnant,
sexually active, used contraceptives or intended to conceive – from early phases of drug trials, research in-
21National Research Act. July 12, 1974. (Public Law 93-348).
22Id.
23Women and Health Research: Ethical and Legal Issues of Including Women in Clinical Studies, Volume 1, supra note 1
at 41.
24Food and Drug Administration (FDA). 1977. General Considerations for the Clinical Evaluation of Drugs. (Rockville,
MD: FDA).
25Id.
10vestigators and institutional review boards tended to extend the policy to all phases of drug trials.26 This
broad interpretation of the FDA guideline was based on concern regarding the well-being of unborn children,
the cost and complexity of recruitment (the most convenient cohorts being predominantly male), the fear of
legal liability of fetal exposure, and the potentially confounding eﬀects from hormonal changes.27 The 1977
guideline however raised important ethical questions about the appropriateness of assuming that women
cannot take steps to avoid becoming pregnant, where necessary, and of deciding for women that protecting
the fetus outweighed other possible interests, questions brought to the forefront by the Belmont Report.28
B. Protecting Human Health: The Advent of Inclusionary Regulations
The publication of the National Commission’s Belmont Report, outlining the ethical principles expected to
govern drug research, was the impetus for the shift away from paternalistic or protectionist policies and
toward a greater valuation of the autonomy of research subjects. The Report identiﬁed three comprehensive
ethical principles that provide an analytical framework for scientists, physicians, research subjects, and
reviewers of research proposals to understand the ethical issues inherent in human subjects research. First,
individuals should be treated as autonomous agents and persons with diminished autonomy are entitled to
protection (respect for persons); second, possible beneﬁts should be maximized and possible harms should
be minimized (beneﬁcence); and third, selection of subjects for clinical research should be fair (justice).29
Subsequent interpretations of this report’s emphasis on respect for persons raised serious questions about
26Women and Health Research: Ethical and Legal Issues of Including Women in Clinical Studies, Volume 1, supra note 1
at 41.
27N.L. Buc. 1993. “Women in Clinical Trials: Concluding Remarks,” Food And Drug Law Journal 48(2): 223-6.
28National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. 1978. The Belmont
Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research (Washington, D.C.: Government
Printing Oﬃce, 1978).
29Id.
11the virtual ban on women of childbearing potential participating in early clinical trials.
Further support for reconsidering the policy of excluding women of childbearing potential from clinical trials
came from a variety of sources. In the 1980s, AIDS activists working to promote access to experimental AIDS
therapies oﬀered the ﬁrst formal challenge to the protectionist policies of the preceding decades. Frustrated
with the length of time required for new drugs to move through the FDA approval process, these activists
urged a new mechanism for earlier release of AIDS drugs in the development process.30 In May of 1987, the
FDA issued regulations that expanded access to experimental drugs used to treat serious and life-threatening
illnesses.31 The success of AIDS activists energized the women’s health movement.
Observing the success of AIDS activists in reorienting ﬁnancial and scientiﬁc resources to better address AIDS
research needs, advocates for women’s health began to push for more focused research on health problems
unique to women. Women had united around health concerns in the 1970s, exempliﬁed by the publication
of Our Bodies, Ourselves,32 a women’s health care manual created in reaction to a health care system that
many women perceived to be unresponsive to their needs, but it was not until the 1980s that women gained
suﬃcient political power to forcefully confront the science and health care bureaucracy. In the late 1980s,
when women of the baby boom generation began to reach mid-life and to experience menopause and breast
and reproductive cancers, these women became increasingly concerned with the relative lack of attention
being paid to women’s health in the scientiﬁc and medical establishments. Better educated and employed
in more powerful positions than their predecessors, baby boom women began to take action by supporting
female political candidates, fund-raising for women’s issues, and forming interest and advocacy groups to
educate themselves and to pressure unresponsive bureaucrats – the same strategies used so successfully by
30D.J. Rothman and H. Edgar. 1990. “New Rules for New Drugs: The Challenge of AIDS to the Regulatory Process,”
Milbank Quarterly Supplement 68(1): 111-142.
31Id.
32Boston Women’s Health Book Collective. 1973. Our Bodies, Ourselves. New York: Simon & Schuster (1973).
12AIDS activists. In addition, dramatic increases in medical school enrollment among women in the 1970s
began to produce a vocal group of medical professionals who questioned current priorities and policies in
women’s health research.33
In 1985, the U.S. Public Health Service Task Force on Women’s Health Issues reported that the “histori-
cal lack of research focus on women’s health concerns has compromised the quality of health information
available to women as well as the health care they receive.”34 The recommendations accompanying the
report provoked NIH in1986 to formulate a new policy that encouraged – but did not mandate – inclusion
of female subjects in all clinical research done by funding recipients.35 The policy also stated that funding
applicants should provide clear rationales for proposed exclusions of women and that investigators should
evaluate gender diﬀerences in their ﬁndings. In 1988, the FDA also published a guidance entitled “Guideline
for the Format and Content of the Clinical and Statistical Sections of New Drug Applications,” emphasizing
the importance of including analyses of demographic data in new drug applications (NDA).36
However, NIH failed to publish implementation guidelines for its policy until 1989, and in 1990, the General
Accounting Oﬃce (GAO) released a report outlining the ineﬀectiveness of the NIH policy, and focusing even
more public attention on the issues of women’s inclusion in clinical research and the implications of this
inclusion for the status of women’s health. In testimony delivered to the House of Representatives, a GAO
representative stated that the unautomated, decentralized recordkeeping had prevented GAO from systemat-
ically evaluating the eﬀectiveness of the NIH policy and that NIH had no way to measure the policy’s impact
on the research it funds. GAO also reported that the 1986 policy had not been well-disseminated internally
33Women and Health Research: Ethical and Legal Issues of Including Women in Clinical Studies, Volume 1, supra note 1
at 42.
34U.S. Public Health Service (USPHS). 1985. “Report of the Public Health Service Task Force on Women’s Health Issues,”
Public Health Reports 100(1): 73-106.
35General Accounting Oﬃce (GAO). 1990. Summary of Testimony by Mark V. Nadel on Problems in Implementing the
National Institutes of Health Policy on Women in Study Populations. Given before the Subcommittee on Health and the
Environment, Committee on Energy and Commerce, House of Representatives, 18 June 1990. (Washington, D.C.: GAO).
36Food and Drug Administration (FDA). 1988. Guideline for the Format and Content of the Clinical and Statistical Sections
of New Drug Applications. (Rockville, MD: FDA).
13to individual institutes or centers, nor to prospective grant applicants and therefore these policies had not
been implemented consistently, if at all. Diﬀerent institutes at NIH also varied in their interpretation of the
policy, adding to its inconsistent application. In addition, the GAO report highlighted some of the larger,
more expensive NIH-funded clinical studies that had included only men as evidence of the ineﬀectiveness of
the policy, such as the Physician’s Health Study, an all-male study of the role of aspirin in the prevention of
heart attacks, and all-male studies of the relationships between caﬀeine and heart diseases, and cholesterol
levels and heart disease.37
After the release of the 1990 GAO report, women’s health advocacy groups and other organizations initiated
their own eﬀorts to clarify the picture of women’s participation in clinical research. Popular opinion which
once supported protective policies began to shift toward labeling these policies paternalistic and discrimi-
natory. The rationales behind clinical studies that had proceeded without question began to be challenged
with questions such as “How could the NIH-sponsored Multiple Risk-Factor Intervention Trials of heart
disease exclude women when women as well as men were dying from heart disease?”38 and “How could
the Baltimore Longitudinal Study of Aging include no women when the elderly population in this country
is disproportionately female?”39 In response to the impact of the GAO report, NIH created the Oﬃce of
Research on Women’s Health (ORWH), and gave it a three-part mandate:
1. to strengthen and enhance research related to diseases, disorders, and conditions
that aﬀect women and to ensure that research conducted and supported by NIH adequately
addresses issues regarding women’s health;
2. to ensure that women are appropriately represented in biomedical and behavioral research
studies supported by NIH; and
3. to foster the increased enrollment of women in biomedical research especially in
pivotal decisionmaking roles within both clinical medicine and the research environment.40
37GAO, 1990, supra note 35.
38Multiple Risk-Factor Intervention Trial Group, Statistical Design Considerations in the NHLI Multiple Risk Factor Inter-
vention Trial (MRFIT). 1977. Journal of Chronic Diseases 30:261-275.
39Women and Health Research: Ethical and Legal Issues of Including Women in Clinical Studies, Volume 1, supra note 1
at 44.
14In 1991, NIH also promulgated a strengthened policy to govern the awarding of federal research grants in
the form of instructions to grant applicants to ensure that women and racial and ethnic groups be included.
For extramural clinical research projects (those carried out by research institutions throughout the U.S. and
the world) “[a]pplications for grants and cooperative agreements that involve human subjects are required
to include minorities and both genders in study populations so that the research ﬁndings can be of beneﬁt
to all persons at risk of the disease, disorder, or condition under study.”41 The applicant must describe the
proposed study population composition and provide a “compelling” justiﬁcation for gender or racial and
ethnic group exclusion. The investigator must also address gender and racial and ethnic issues in “develop-
ing a research design and sample size appropriate for scientiﬁc objectives of the study.”42 Although what
constitutes a “compelling” reason for exclusion is not deﬁned, the explanatory memorandum to NIH staﬀ
and peer advisory groups accompanying the policy directs them to consider suﬃcient only “strong scientiﬁc
or practical reasons for the exclusion of women or racial and ethnic groups from clinical research.”43 Some
of the potentially acceptable justiﬁcations listed include research on a predominantly or exclusively male
condition, research that presents an unacceptable risk for women of childbearing age, certain pilot and fea-
sibility studies in which gender diﬀerences may not be germane, research in an area that has already been
extensively studied in women, and, in certain instances, studies that would be prohibitively expensive.44 In-
tramural research projects (operated by federal employees on NIH campuses) were subject to a less restrictive
policy, requiring only that gender-based exclusions be indicated and a clear rationale be provided. Finally,
NIH devised a plan to facilitate the implementation of the new policy, including educational programs for
41National Institutes of Health and Alcohol, Drug Abuse, and Mental Health Administration (ADAMHA). 1990.
“NIH/ADAMHA Policy Concerning Inclusion of Women in Study Populations.” NIH Guide 19(31): 18-19.
42Id.
43Id.
44National Institutes of Health (NIH). 1990. “NIH Instruction and Information Memorandum OER 90-5.” December 11.
15reviewers, investigators, and NIH staﬀ, and for a coding system to track gender and racial and ethnic group
representation in clinical studies.45
The GAO issued a second report in 1992 addressing the inclusion of women in clinical trials, and exam-
ining the FDA’s policies and the pharmaceutical industry’s practices regarding experimental drug testing
in women.46 The report stated that although women were included in most of the drug studies reported
by pharmaceutical companies that had secured FDA approval for a new drug between January 1988 and
June 1991, for more than sixty percent of the drugs, the representation of women in the test population was
less than the representation of women in the population with the corresponding disease. Representation of
women was found to be particularly poor in cardiovascular drug trials, a ﬁnding about which the GAO was
especially concerned because this is an area in which gender diﬀerences in drug response had been observed.
In addition, GAO indicated that pharmaceutical manufacturers frequently failed to analyze trial data for
gender diﬀerences.47
C. Current Regulations and Policies: What is the Law Today?
Finally, on June 10, 1993, the NIH Revitalization Act, which grew out of the Women’s Health Equity Act
introduced in 1990 and calling for among other things the inclusion of women and racial and ethnic groups
in NIH-sponsored or funded clinical research, was signed into law by President Clinton.48 The Act requires
45ADAMHA, 1990, supra note 41.
46General Accounting Oﬃce (GAO). 1992. “Women’s Health: FDA Needs to Ensure More Study of Gender Diﬀerences in
Prescription Drug Testing.” GAO/HRD-93-17. Washington, D.C.: GAO.
47Id.
48NIH Revitalization Act of 1993 (Public Law 103-43). Reintroduced in 1991, the Women’s Health Equity Act (WHEA)
contained 22 bills that addressed research, care, and prevention issues in women’s health. During the 1991-1992 legislative
year, six of the research-related provisions of the WHEA (including the provision to permanently authorize the ORWH)
were incorporated into the NIH Revitalization Act. These provisions authorized additional funding for breast cancer, ovarian
and other reproductive cancers, and osteoporosis and other bone disorders; they also called for the establishment of three
16that women and racial and ethnic groups be included as subjects in each intramural and extramural clinical
research project supported by NIH. It further requires that any NIH-funded clinical trial that includes women
and racial and ethnic minorities as participants be designed and carried out so as to provide for valid analysis
of whether the variables being studied aﬀect these subpopulations diﬀerently from other participants in the
trial. Cost may be considered only when the data regarding women or members of minority groups that would
be obtained in the project have been or will be obtained through other means that oﬀer comparable quality;
otherwise, cost is not an appropriate reason for excluding women. The inclusion of women and minorities
may not be required if substantial scientiﬁc data demonstrate that there is no signiﬁcant diﬀerence between
the eﬀects of the intervention or variables under study on these groups and the eﬀects on the subjects included
in the trial. Furthermore, NIH is instructed to conduct or support outreach programs for recruitment and
retention of women and racial and ethnic group participants in clinical research projects. The law, however,
does allow for exemption in cases of research that are inappropriate with respect to the health of the subjects,
the purpose of the research, or other circumstances determined by NIH.49
On July 22, 1993, the FDA released a new guideline, “Guideline for the Study and Evaluation of Gender
Diﬀerences in the Clinical Evaluation of Drugs,” lifting the 1977 guideline recommending the exclusion
of women of childbearing potential from early clinical trials, including pharmacology studies and early
therapeutic studies.50 The introduction to this guideline indicates that the broad principles that are outlined
for the inclusion of women in the early phases of clinical trials will also be applied to FDA approval processes
for biological products and medical devices. The guideline explains that subjects in a given clinical study
should reﬂect the population that will receive the drug when it is marketed, and suggests that patients of both
contraceptive research centers and two fertility research centers. One of the provisions included a policy regarding inclusion of
women and racial and ethnic groups in NIH-sponsored or –funded clinical research.
49Id.
50Food and Drug Administration (FDA). 1993. “Guideline for the Study and Evaluation of Gender Diﬀerences in the Clinical
Evaluation of Drugs,” Notice, Federal Register 59(139): 39406-39416.
17genders be included in the same trial to permit direct comparison of genders within the studies. The guideline
also explicitly discredits routine exclusion of women from bioequivalence trials because changes during the
menstrual cycle may cause intrasubject variability. Inclusion of women in these studies is expected to indicate
if there is a possible need for concern about the variations in response to a drug based on the hormonal
variations of the menstrual cycle. The guideline outlines the FDA’s expectations for the data analyses of
gender diﬀerences and other subgroup diﬀerences, and expects these analyses to be preformed and explained
in an application for approval of a new drug. The guideline emphasizes the importance of pharmacokinetic
(the eﬀect of the body on the drug) studies to deﬁne gender-related diﬀerences in drug responses, but does
not expect pharmacodynamic (the eﬀect of the drug on the body) and eﬀectiveness studies to be conducted
separately on men and women unless the analyses by gender of clinical trials and pharmacokinetic studies
indicate signiﬁcantly diﬀerent gender-related response. Finally, the guideline reiterates the FDA’s belief
that large-scale exposure of women of childbearing potential should not take place until after the results
of animal toxicity tests are analyzed, and recommends that clinical protocols include provisions for the use
of contraception or abstinence for the entire time a subject will be exposed to the drug. In the clinical
evaluation of drugs that carry the risk of causing abnormalities in reproductive organs or their function (as
identiﬁed in animals), the risks of exposing individuals of reproductive potential must be weighed against
the potential beneﬁts of the drug.51
More recently, the Food and Drug Administration Modernization Act of 1997 amended Section 505(b)(1) 21
U.S.C. 355 (b)(1) by adding “The Secretary shall, in consultation with the Director of the National Institutes
of Health and with representatives of the drug manufacturing industry, review and develop guidance, as
appropriate, on the inclusion of women and minorities in clinical trials...”52 This Act mandates neither the
51Id.
52Food and Drug Administration Modernization Act. 1997. Sec. 115 Clinical Investigations. (b) Women and Minorities.
18inclusion nor the exclusion of women from clinical trials. The Center for Drug Evaluation and Research
(CDER) was assigned the responsibility for reviewing and implementing this section of the FDAMA for the
FDA, and to accomplish that task established the FDAMA Women and Minorities Working Group with
representation from the FDA and the National Institutes of Health.53
In 1998, the Working Group concluded that additional guidance on the inclusion of women in clinical trials
was not needed.54 In coming to this conclusion, the Group reviewed and evaluated existing guidance regard-
ing the inclusion of women and minorities in clinical trials, speciﬁcally, the 1988 “Guideline for the Format
and Content of the Clinical and Statistical Sections of New Drug Applications,”55 the 1993 “Guideline for
the Study and Evaluation of Gender Diﬀerences in Clinical Evaluations of Drugs,”56 the 1998 regulation
“Final Rule: Investigational New Drug Applications and New Drug Applications,”57 and the 1998 proposed
clinical hold rule “Investigational New Drug Applications; Proposed Amendment to Clinical Hold Regula-
tions for Products intended for Life-Threatening Diseases.”58 The Group found that taken together these
guidelines and regulations, which are still in eﬀect, provide suﬃcient guidance concerning the inclusion of
women and minorities in clinical research and ensure that women are included appropriately in clinical tri-
als and that data is analyzed to ensure that gender information is available and understood.59 The 1988
guideline emphasizes the importance of including analyses of demographic data in NDA applications. The
1998 regulation requires that analyses of eﬀectiveness and safety data for important demographic subgroups,
including gender and racial subgroups, be submitted in NDAs and that enrollment of subjects into clinical
studies for drug and biological products be tabulated by important demographic subgroups (age group, gen-
Rockville, MD: FDA.
53FDAMA Women and Minorities Working Group Report, July 20, 1998 (visited February 2002) <http://www.fda.gov>.
54Id.
55FDA, 1988, supra note 36.
56FDA, 1993, supra note 50.
5721 CFR Parts 312 and 314, February 11, 1998.
5821 CFR Part 312, infra note 61.
59FDAMA Women and Minorities Working Group Report, supra note 53.
19der, and race) in investigational new drug (IND) annual reports. This ﬁnal rule allows the FDA to refuse
to ﬁle any NDA that does not analyze safety and eﬃcacy information appropriately by gender. The critical
importance of including all appropriate subsets of the population in product development, according to the
Group, is clearly articulated in the 1993 guideline, which states:
In general, drugs should be studied prior to approval in subjects representing a full range
of patients likely to receive the drug once it is marketed. Although in most cases, drugs
behave qualitatively similarly in demographic (age, gender, race) and other (concomitant
illness, concomitant drugs) subsets of the population, there are many qualitative diﬀerences,
for example, in dose-response, maximum size of eﬀect, or in the risk of an adverse eﬀect.
Recognition of these diﬀerences can allow safer and more eﬀective use of drugs. Rarely, there
may be qualitative diﬀerences as well. It is very diﬃcult to evaluate subsets of the overall
population as thoroughly as the entire population, but sponsors are expected to include a full
range of patients in their studies, carry out appropriate analyses to evaluate potential subset
diﬀerences in the patients they have studied, study possible pharmacokinetic diﬀerences
in patient subsets, and carry out targeted studies to look for subset pharmacodynamic
diﬀerences that are especially probable, are suggested by existing data, or that would be
particularly important if present.60
Finally, the 1998 proposed clinical hold rule (the ﬁnal rule was published in June of 2000) expands upon
this guidance by allowing the FDA to place a clinical hold on one or more studies under an IND if a sponsor
proposes to exclude men or women with reproductive potential from participation in an investigation only
because of risk or potential risk of reproductive or developmental toxicity from the use of an investigational
drug product.61 The Group believed that any lingering exclusionary policies would be addressed by the
ﬁnalization of the 1998 proposed rule.
In summary then, a variety of policies and regulations currently exist concerning the inclusion of women in
clinical trials. How these various policies and regulations ﬁt together is somewhat complex. NIH, located
within the Public Health Service of the Department of Health and Human Services, is the single largest
supporter of biomedical and behavioral research (health R&D) and development in the world.62 NIH un-
6121 CFR Part 312, June 1, 2000, Final Rule: Investigational New Drug Applications; Amendment to Clinical Hold Regula-
tions for Products intended for Life-Threatening Diseases.
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20derwrites approximately 73 percent of all health R&D supported by the U.S. federal government.63 Thus,
research sponsored, funded, or conducted by the NIH is subject to the NIH Revitalization Act of 1993 which
requires the inclusion of women in NIH-sponsored or funded clinical trials and the analysis of subgroup dif-
ferences. The FDA, also a Public Health Service agency, functions under the Food Drug, and Cosmetic Act
(FDCA) which gives the commissioner of the FDA the authority and responsibility to regulate the testing
and marketing of drugs, biologics, and medical devices.64 The FDAMA of 1997, which governs the FDA,
does not require the inclusion of women in clinical trials. Although the 1993 FDA guideline encourages
the inclusion of women and the analysis of gender diﬀerences, these guidelines do not have the force of law
or regulation which guide the FDA, are not binding on the FDA, and do not create or confer any rights,
privileges, or beneﬁts for or on any person. These guidelines are provided as an aid to organizations involved
in the evaluation of new drugs for FDA approval who wish to market such drugs. The guideline does not
mandate the inclusion of women of childbearing potential, or women in general, relying instead on the “in-
terplay of ethical, social, medical, legal, and political forces” to encourage greater participation of women
in the earlier stages of clinical trials.65 Institutions that conduct clinical trials and research funded by NIH
involving drugs, biologics, or medical devices are subject to all applicable policies and regulations of both
NIH and FDA.
Currently, this means that, according to the NIH Revitalization Act, funding can be denied if women are
excluded from clinical trials, according to FDA’s 1993 guideline, women should be included in clinical trials,
according to the FDAMA, women are not required to be included in clinical trials, and according to the
2000 clinical hold rule, the FDA can place a clinical hold on studies under an IND that have excluded men
at 129.
63Id.
64Id. at 131.
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21or women, but does not require this action. Thus, the bottom line is that, funding aside, current law does
not require the FDA to include women in clinical drug trials. Although the NIH funds most of these trials
and requires women to be included, the FDA itself is governed by no such regulation. Therefore, the FDA
can, in theory even if not in practice, exclude women, despite the fact that the 1993 guideline encourages the
inclusion of women in clinical trials, thereby reﬂecting a policy position diﬀerent from the FDA’s regulatory
position.
22PART II: Exclusion v. Inclusion: Arguments For and Against Including Women in Clinical
Trials
The historical evolution of federal policies regarding women’s participation in clinical studies over the past
several decades arises from the conﬂict between two public policy positions: protectionism and access.66
Emphasis on the need to protect research subjects burgeoned in the 1950’s and 1960s in response to revela-
tions of abuses of the research process. This emphasis was reinforced by the discovery of adverse outcomes
in the children of women who had taken certain drugs during pregnancy. The legislation passed in the mid-
1970s was designed to protect research subjects from unethical treatment. The regulations and guidelines
stemming from this legislation also were designed to protect against fetal injury in their restrictions on the
inclusion of pregnant women and women of childbearing potential in drug trials. In later years, however,
these guidelines and regulations put in place to protect research subjects were challenged by claims that they
were overprotective and overly exclusive, and therefore detrimental to the health of the very persons they
were intended to protect. As a result, new guidelines and regulations emerged to promote increased access
to health care and greater patient autonomy. This change in policy, however, remains controversial.
While most health care advocates, researchers, and academics in the ﬁeld would agree that women’s health is
a serious issue deserving attention, these same individuals continue to disagree about whether this attention
should manifest itself in the form of including women in clinical trials. There exist a variety of rationales
and arguments both for and against the inclusion of women of childbearing potential in clinical trials, all of
which must be considered before one can form an opinion on the subject.
A. Rationales for Including Women of Childbearing Potential in Clinical Trials
66J. A. Sechzer, V.C. Rabinowitz, F.L. Denmark, M.F. McGinn, B.M. Weeks, C.L. Wilkens. 1994. “Sex and Gender Bias in
Animal Research and in Clinical Studies of Cancer, Cardiovascular Disease, and Depression.” In: Forging a Women’s Health
Research Agenda: Policy Issues for the 1990s. A. Sechzer, A. Griﬃn, and S.M. Pfaﬄin, eds., (New York, New York: New York
Academy of Sciences, 1994).
23Rationales for including women of childbearing potential in clinical trials by lifting the 1977 guideline fa-
voring their exclusion include the detrimental eﬀect that exclusion has on women’s health in general, the
identiﬁcation of gender-related variations in drug eﬀects and response, the valuable knowledge that results
from the inclusion of women which oﬀsets any increased cost of inclusion, respect for women’s autonomy
and decision-making capacity in reproductive issues, and the potential for liability that may result if women
are excluded from clinical trials.
1. Eﬀect of Exclusion on Women’s Health Care
When women are excluded from clinical trials, the development of clinical data relevant to women’s health
is inhibited. More importantly, the risk to women’s health increases. If women were excluded from clinical
trials, after FDA standards for drug approval and drug marketing are met, pharmaceuticals that were never
tested on women would be used by women, and in some cases women would be the primary users, despite the
fact that there would be no clinical basis for predicting the eﬀects of such drugs in women. Not only would
side-eﬀects occur in a certain percentage of women who took these drugs, but those side-eﬀects would involve
many more women because the population exposed to potential side-eﬀects would be much larger during
mass consumer marketing than during clinical trials. Furthermore, when interventions are not adequately
studied in women, women’s medical care may be seriously compromised; physicians may choose not to
give female patients available treatments, or the treatments physicians give these patients may pose greater
risks to women than to men. Literature in the ﬁeld indicates “residual exclusion” of women from access
to medications tested only in men;67 physicians are reluctant to use drugs in populations for which safety
67H. Minkoﬀ, J.D. Moreno, and K.R. Powderly. 1992. “Fetal Protection and Women’s Access to Clinical Trials,” Journal of
24has not been demonstrated during clinical trials. Other research indicates that women may be diagnosed
later or receive less aggressive treatment than men for speciﬁc conditions, most notably studies concerning
patients with kidney disease gaining access to dialysis and transplantation, the diagnosis of lung cancer by
sputum cytology, and the diagnosis of heart disease. Several studies ﬁnd that women with heart disease
may be diagnosed later than men and that women are less likely than men to have invasive procedures
such as coronary angioplasty or coronary artery bypass surgery. Finally, lower case survival rates have been
observed in women following myocardial infarction and diagnosis of AIDS, reﬂecting later diagnosis and less
aggressive treatment.68 Excluding women from clinical studies thus appears to result in information deﬁcits
regarding how women respond to drugs and the causes of morbidity and mortality in women, deﬁcits with
severe consequences for women’s health.
2. Gender-Related Variations in Drug Eﬀects and Response
Implicit in the 1993 guideline reversing the 1977 guideline and in the policy of inclusion mandated by the
NIH Revitalization Act of 1993 is the underlying assumption that there are meaningful diﬀerences between
the sexes and that the results of male-only studies cannot be reliably or safely generalized to women. If men
and women responded identically to therapy, the issue of representation of women in clinical trials would be
less important. Indeed, there is a general belief among researchers that, in most situations, women and men
will not diﬀer signiﬁcantly in their responses to treatment.69 Even for diseases where men and women diﬀer
signiﬁcantly in the likely time of onset, such as heart disease, most clinical researchers would argue that men
and women respond in much the same way to treatment and experience a similar evolution of the disease.
The reasons for this belief are rooted in several observations regarding health problems relevant to both men
Women’s Health 1:137-140.
68C.S. Weisman and S.D. Cassard. 1994. “Health Consequences of Exclusion or Underrepresentation of Women in Clinical
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25and women: for the majority of drug treatments, eﬃcacy and safety do not depend on such factors as body
mass, adipose tissue, hormones, or other factors associated with gender; treatments by surgical procedure
for diseases associated with both genders seldom diﬀer because the patient is female rather than male, and
to the extent that women may be treated diﬀerently, it is because of factors associated with gender but not
speciﬁc to gender, such as bone mass and organ size; and a long history of nonhuman research supports the
conclusion that subgroup diﬀerences are rare.70
Nevertheless, there is concern in the ﬁeld that clinicians may be too quick to assume that there are no
diﬀerences between men and women, rather than testing for gender-related eﬀects.71 Although signiﬁcant
gender diﬀerences in drug response have not been detected in the majority of cases, when they are detected,
these diﬀerences can be highly signiﬁcant in terms of diagnosis and treatment, thus emphasizing the need
for clinical investigators to ascertain under what conditions such gender diﬀerences are likely to occur and
to design clinical studies accordingly. In other words, where gender diﬀerences are evident, the results of
medical research conducted on men cannot be generalized to women without suﬃcient evidence, via inclusion
of women in clinical trials, that the results in fact apply to women.
a. Diﬀerences Between Men and Women
For the purposes of health research, there are many meaningful diﬀerences between the sexes which have
implications for how clinical trials should be carried out, particularly in terms of including women in these
trials. These diﬀerences by gender include diﬀerences in body size, composition, and metabolism, diﬀerences
in aging, behavioral and psychosocial diﬀerences, and hormonal diﬀerences. On average, women are smaller
70Id.
71Id. at 85.
26than men in weight, height and surface area; this may aﬀect drug dosing, which may be more accurately
based on body weight or surface area than on a ﬁxed dose, as most adult dosing is done. If a drug is
administered on the basis of body weight or surface area, the average adult male will receive a larger dose
than the average adult female. If weight or surface area are not taken into consideration however, and men
and women are given the same dose, then the average male will in fact receive a smaller dose per pound of
body weight or per inch of surface area than the average female. If the drug has minimal toxicity or a wide
therapeutic index,72 these diﬀerences in dosage may be of little consequence, but if the therapeutic index is
narrow or the toxicity severe, these diﬀerences may be of critical importance. Compared with men, women
also have a lower ratio of lean body mass to fatty tissue, a diﬀerence that may aﬀect drug disposition because
the water content and metabolism of fatty tissue and muscle tissue diﬀer. Lipid-soluble drugs have a greater
volume of distribution in women, thereby aﬀecting the appropriate therapeutic dose. The metabolism of
men, at all ages after sexual maturation, is also higher than that of women. Drug metabolism diﬀerences by
gender are not well-understood but are clearly demonstrated by drugs such as nicotine, aspirin, and some
anticoagulants. Men and women also diﬀer in the presence and concentration of hormones within the body,
such as estrogen, progesterone, prolactin and testosterone, and in their concentrations of serum iron, uric
acid, creatinine phosphokinase, and gamma glutamyl transpeptidase. Hormonal diﬀerences may alter the
pharmacokinetics and pharmacodynamics of certain drugs while diﬀerences in other element concentrations
are important in distinguishing the normal from the abnormal in selected disease states.73
Women live longer than men by an average of seven years and presently constitute ﬁfty-nine percent of those
over age sixty-ﬁve and nearly seventy-ﬁve percent of those over age eighty-ﬁve. While many of the medically
72Therapeutic index refers to the doses, blood concentration, or receptor concentration necessary to achieve a positive
therapeutic response versus those amounts that elicit a toxic response.
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27and scientiﬁcally relevant diﬀerences that exist between younger men and women persist into old age, men
and women over age sixty-ﬁve also experience gender-related health problems that are unique to their age
group. Women over sixty-ﬁve suﬀer more adverse events related to medication than do men in the same
age group. Although older men and women both experience decreases in lean body mass and increases in
fat tissue as a fraction of body weight, these changes are more pronounced in women, such that certain
drugs may have a more immediate toxic eﬀect or a more prolonged eﬀect in older women than in older
men. Men and women over sixty-ﬁve also diﬀer with respect to the diseases and conditions that commonly
aﬀect them. Older women are aﬀected by rheumatoid arthritis three times more frequently than men, and
osteoporosis, digestive disorders, and thyroid diseases are far more common in women than men. Mental
health problems, such as depression, anxiety disorders, sleep disorders, mania, and late-onset psychosis also
aﬄict older women to a greater extent than older men, and neurodegenerative diseases such as Alzheimer’s
disease and certain movement disorders aﬀect women disproportionately.74
Men and women further diﬀer in several psychosocial variables, most of which pertain to gender roles and
lifestyle, that can aﬀect disease risk and treatment. There are stresses associated with the multiple roles
women typically assume in taking on the responsibilities of balancing work and family that many men
never experience. Women also are more likely to be the victims of domestic violence leading to physical
and psychological injuries. Lifestyle diﬀerences between men and women include the fact that women tend
to exercise less regularly than men and that women drink less alcohol and smoke tobacco less than men.
Cultural emphasis on thinness and beauty in women translate into a higher prevalence of eating disorders
and high use of over-the-counter diet pills as compared with men.75
In addition to the ways in which men and women diﬀer as a matter of degree, men and women also diﬀer
74Id. at 89-90.
75Id. at 90-91.
28in ways speciﬁc to one gender. Between menarche and menopause, women experience the menstrual cycle
characterized by ﬂuctuating levels of the hormones estrogen and progesterone. These hormonal changes can
aﬀect drug disposition such that females may beneﬁt from variable drug dosing tailored to their menstrual
cycles. Hormones may also aﬀect the success of some surgical treatments. Menopause is also unique to
women and the characteristic end in the production of estrogen, as well as the fact that many women engage
in estrogen replacement therapy to reduce or eliminate the unpleasant symptoms associated with menopause,
can aﬀect women’s risk of certain diseases.76
In sum, all of these diﬀerences between men and women have important consequences for clinical trials.
Diﬀerences in size, fat ratios, and metabolic rates are associated with diﬀerences in drug concentration,
metabolism, and response. Psychosocial diﬀerences are associated with diﬀerences in risk factors and in
adherence to experimental protocols. These diﬀerences can further change over time, both in the short term
– during the menstrual cycle – and long term – with aging. Advocates for inclusion argue that women must
be included in clinical trials because of these signiﬁcant diﬀerences between men and women.
b. Evidence of Gender Diﬀerences in Drug-Response
Several studies have shown that existing gender diﬀerences do in fact aﬀect drug response. After a heart
attack, the response of women to agents for combating thrombosis is unequal.77 Women show less beneﬁt
than men from oral anticoagulants and thrombolytic agents with respect to reduced mortality.78 Women
also have more bleeding episodes with thrombolytic agents.79 This is especially signiﬁcant because women
are twice as likely as men to have a second heart attack within a year of the ﬁrst. Their lesser therapeutic
response may explain why women are twice as likely as men to die within the ﬁrst few weeks after a ﬁrst
myocardial infarction, and emphasizes the need for heart attack treatments to be tested on women. Women’s
76Id. at 91.
77W.M. Davis. 1998. “Impact of Gender on Drug Responses,” Drug Topics, October 5, 1998.
78Id.
79Id.
29response to antihypertensive drugs also diﬀers from that of men, and young and middle-aged women are
found to suﬀer more adverse eﬀects from hypertension therapy than men.80 Women have been found to take
twice as long as men to wake up from anesthesia and the class of painkillers called kappa opioids seem to
work twice as well for women as for men.81 The fact that women respond diﬀerently to so many treatments
supports their inclusion in clinical drug trials.
c. Impact of Diﬀerences on Clinical Trial Design
Because men and women diﬀer in these ways, clinical drug trials must be designed to take into account gender-
related variations in drug eﬀects and response. This design, women’s health advocates argue, not only fosters
inclusion of women in clinical trials but also serves to promote scientiﬁc validity. Methodological implications
of gender equity in clinical trials include concerns about external and internal validity, homogeneity versus
heterogeneity, and subgroup analysis of interaction eﬀects. When women are excluded from clinical trials,
external validity – the ability to generalize the ﬁndings obtained from a sample to a broader population
– is jeopardized since women clearly exist in the population but are not represented in the sample.82 It
should be mentioned that in practice, external validity in any clinical trial is an oxymoron. External validity
is based on drawing a representative sample of the population of interest. Clinical trials, however, do not
take a random sample from a representative population; rather, the members of a study cohort diﬀer from
the population about which inferences are to be made in several important ways. Study participants are
volunteers. These volunteers are screened to see if they meet selection criteria, and then randomized into
treatment and nontreatment groups. The inclusion and exclusion criteria produce a more narrowly deﬁned
set of subjects than the group that may be eligible for treatment. To minimize the number of subjects
80J.L. Willis. 1997. FDA Consumer Special Report. “Equality in Clinical Trials: Drugs and Gender.” In: Your Guide to
Women’s Health, Third Edition, Oﬃce of Special Health Issues (placed on the web Dec. 24, 1997) (visited February 2002)
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81Id.
82R.B. Merkatz, R. Temple, S. Sobel, K. Feiden, D.A. Kessler, et al.. 1993. “Women in Clinical Trials of New Drugs: A
Change in Food and Drug Administration Policy,” New England Journal of Medicine 329 (4): 292-6.
30who drop out for instance, clinical trials often exclude people who plan to change residence during the
follow-up period, people likely to die soon from a disease other than the one being investigated, and people
the investigators believe will not follow the requirements of the protocol.83 Thus, achieving true external
validity is practically impossible. However, despite the fact that clinical trials cannot truly speak to external
validity, this design can achieve internal validity – how consistently and how well the treatment works.84
Clinical trials can illuminate gender diﬀerences in treatment eﬀects, and in that sense can contribute to
the knowledge and understanding of how women and men diﬀer in their responses to treatment. When a
response to a treatment cannot be generalized from the sample to the population as a whole, it is essential
that enough members of the relevant subgroups be included in the sample so that a diﬀerential response can
be detected and measured. Including women in clinical trials means that even if a study has no external
validity, the study will have value due to its internal validity.
In order to assess the eﬀect of treatment, clinical trials in general must balance conﬂicting desires for
homogeneity and heterogeneity.85 Ideally, the study cohort is homogenous enough to yield a high probability
of learning whether a therapy is safe and eﬀective but heterogeneous enough to ensure that the observed
results are not applicable only to a narrowly deﬁned subgroup. Clinical investigators try to reduce or
eliminate sources of variance that are under their control in order to isolate the eﬀects of the drug on study
participants from eﬀects due to diﬀerences among the study participants; to do this, investigators construct
criteria for the selection of subjects that are intended to reduce variance by recruiting the most homogenous
sample possible. The smaller the anticipated sample size of the trial the more important it is to recruit a
homogenous sample with regard to factors known to aﬀect treatment. Variations in the population enrolled
in a small trial can have a greater eﬀect on the results than in a large trial because randomization into
83Id.
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31treatment groups is more likely to serve its purpose in a large trial than in a small one. In addition, the
ability to adjust for diﬀerences in the composition of the study groups through regression techniques is limited
if not completely precluded in a small trial while it is the method of choice for adjustment in large trials.
However, at the same time that investigators seek a homogenous sample, in some situations a homogenous
response cannot be assumed for speciﬁc subgroups of the population. Where this is true, it is essential
that the sample be suﬃciently heterogeneous by including enough members of the relevant subgroups in the
sample to ensure that the results are applicable to those not included in the sample. Exclusion of a given
subgroup from a study precludes formal inferences about the expected results for that subgroup. In the case
of women, the previous discussion indicates that the existing diﬀerences between men and women make it
impossible to assume a homogenous response when women are excluded and thus precludes formal inferences
from a male-only sample to the population as a whole.
While all investigators must balance the beneﬁts of using homogenous samples – isolating drug eﬀects – with
the importance of including subgroups such as women – making their research meaningful beyond the study
itself, advocates for inclusion argue that the known diﬀerences between men and women and the eﬀect of
these diﬀerences on drug response clearly support the inclusion of women in clinical drug trials and outweigh
investigators’ desire for homogeneity in their samples. Taking into account the myriad diﬀerences between
men and women and the importance of being able to generalize study results from the study sample to the
population, investigators need to include women in their research if they hope to generalize their results to
this subgroup.
3. Valuable Knowledge Oﬀsets Any Increased Cost
32Including women in clinical trials is also supported by the fact that the cost and eﬃciency gains that investi-
gators’ use to justify excluding women may not be valid and, if valid, are oﬀset by the gains in knowledge that
result when women are included. In the 1970s, women were excluded from two large preventative clinical
trials, as previously discussed – the Physicians’ Health Study and the Multiple Risk Factor Intervention Trial
(MRFIT). The primary reason for excluding women from the Physicians’ Health Study was the gender mix
of the physician cohort approached for study, ninety percent of which was male.86 The number of women
in the cohort was not large enough for a gender-by-treatment interaction analysis. Despite the fact that
the investigators’ reservations about their ability to perform such an analysis were valid, enrollment of a
speciﬁed subgroup does not obligate them to perform interactive analysis for that subgroup, nor does the
analysis need to be deﬁnitive if performed. Even without this analysis, the sign and size of any diﬀerence
observed for women, had they been included, would have provided some general indication of whether the
result obtained in men is consistent with that observed in, and thus generalizable to, women. Women may
also have been excluded from clinical trials for reasons of eﬃciency. If the increase in information gained
was not proportionate to the increased costs of including women, perhaps it was rational to exclude women.
For example, if including women would have resulted in a ten percent increase in person-years of follow-up
information, then to justify excluding women it would be necessary to show that including them would
have increased costs by more than ten percent.87 In the case of the Physicians’ Health Study, including
women would likely have added valuable follow-up information without adding disproportionate costs since
the costs for screening, treatment, and follow-up of each participant were relatively low. The exclusion of
women from MRFIT was also based on scientiﬁc and eﬃciency grounds. Screening costs were high because
it was necessary to ﬁnd people with a deﬁned risk proﬁle based on smoking behavior, cholesterol level, and
blood pressure, assessments which required the collection and analysis of blood and blood pressure and
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33individual interviews.88 Nearly 362,000 men were screened to produce the 12,866 men enrolled in the trial;
had women been included, the cost of the trial would have been substantially higher. Nonetheless, those in
favor of including women in clinical trials argue that including women in trials like these produces valuable
information which oﬀsets the increased cost.
4. Respect for Women’s Autonomy and Decision-Making Capacity
From an ethical perspective, the exclusion of women of childbearing potential from clinical trials implies
a lack of respect for their autonomy and decision-making capacity concerning reproductive issues. The
ethical principles articulated in the Belmont Report – respect for persons, beneﬁcence, and justice – as
well as recent Supreme Court decisions suggest that women should have the right to make their own risk-
beneﬁt choices about their potential pregnancies and their participation in clinical trials.89 The Belmont
Report’s acknowledgement that individuals should be treated as autonomous agents and only those persons
with diminished autonomy should be protected promotes a woman’s right to chooses whether or not to
participate in a clinical trials, rather than to be excluded in a paternalistic eﬀort to protect her well-
being. The Pregnancy Discrimination Act,90 as interpreted by the Supreme Court in the landmark case
of United Automobile Workers v. Johnson Controls,91 prohibits the blanket exclusion of pregnant women
from jobs they are qualiﬁed to perform solely because working conditions pose potential risks to exposed
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34fetuses. Although the purposes of clinical trials are manifestly diﬀerent from the purposes of employment,
the Court’s emphasis in Johnson Controls on a woman’s right to participate in decisions about fetal risk
underscores the principle of autonomy and further promotes allowing women the right to choose whether to
participate.
Assessing the potential risks and beneﬁts of clinical research is not an easy task, nor is it a process that
enjoys mathematical precision. People disagree in their evaluations of the magnitude of risks and beneﬁts
and how to weigh risks against potential beneﬁts, and diﬀerent people – be they medical scientists, patients,
or healthy volunteers – value the risks and beneﬁts diﬀerently. Some may consider certain risks worth
taking in relation to potential beneﬁts, while other risks may be viewed as unacceptably high in relation
to potential beneﬁts. Assessing risks and beneﬁts has both a scientiﬁc component and a personal element.
The scientiﬁc component is more objective: based on observations, previous studies, and clinical experience,
scientists and researchers agree on what risks might be expected, how likely they are to occur, and their
impact on morbidity and mortality, and the beneﬁts that are anticipated. At the same time, the risk-beneﬁt
assessment has an inherently personal element. Assessing risks and beneﬁts is colored by individual values
and the meaning of the risks and beneﬁts in an individual’s life or the lives of others. Women’s values
can diﬀer signiﬁcantly from those of scientists (whether male or female) is assessing risk-beneﬁt ratios. For
example, women’s health advocates tend to deﬁne the “safety” of contraceptive methods in terms quite
diﬀerent from those typically employed by biomedical scientists:92
Scientists’ concern is to establish safety of methods according to speciﬁc measurable pa-
rameters. They assess toxicity, ﬁrst in animals and then in carefully controlled stud-
ies in human volunteers. Subsequent studies address eﬃcacy and short- to medium-term
safety...Women’s health advocates...give more priority to methods that have fewer side
eﬀects and that protect against sexually transmitted diseases and their consequences such
as infertility. While scientists have tended to give priority to methods which minimize users’
control, women’s health advocates prefer methods controlled by the users.93
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35Thus, including women of childbearing potential in clinical studies evidences a greater acknowledgement of
individual values and a respect for personal decision-making.
In addition to the fact that allowing women to participate in clinical trials promotes respect for women’s au-
tonomy and decision-making capacity in reproductive issues, inclusion is arguably constitutionally required.
All laws and policies of state and federal government are expected to conform to the U.S. Constitution –
the ultimate source of legal authority in this country. The Fourteenth Amendment’s provision that “No
state...shall deprive any person of life, liberty, or property” is particularly relevant to questions of partic-
ipation in clinical research.94 The Fourteenth Amendment, and the Bill of Rights in general, have been
interpreted by the Supreme Court to require equal access to government health beneﬁts, a high degree of
personal liberty in matters aﬀecting health care, and decisional privacy. The Fourteenth Amendment pro-
tects the rights to bodily self-determination and personal decision-making about matters closely aﬀecting
health. The Supreme Court has upheld the right to decisional privacy with regard to termination of artiﬁcial
nutrition and hydration95 and abortion;96 the Court reaﬃrmed the right to private abortion decision-making
in Planned Parenthood of Southeastern Pennsylvania v. Casey,97 in which it recognized the right of a women
“to choose to have an abortion before viability and to obtain it without undue interference from the State.”98
While acknowledging a state interest in the life of at least some fetuses, the Court stressed the importance
of reproductive privacy for women’s liberty, linking a woman’s unique reproductive liberty to her ability “to
participate equally in the economic and social life of the nation.”99 It is diﬃcult to predict what standard of
review will apply in future Fourteenth Amendment privacy cases aﬀecting women’s health, including cases
involving exclusion from research, because although strict scrutiny was applied in Roe v. Wade, rational ba-
94U.S. Const. Amend. XIV.
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36sis was applied in Cruzan, and an intermediate standard of review was applied in Casey. Nonetheless, there
is an argument that Cruzan’s recognition of a right to refuse artiﬁcial nutrition and hydration, premised on
freedom from intervention in private decision-making related to health care, also implies a right to take part
in risky clinical studies; that is, if one can terminate one’s own life, one should be able to assume the risk of
taking an untested drug.100
5. Liability for Exclusion of Women
Excluding women from clinical trials has long been viewed as a means of avoiding claims for injuries incurred
during the studies, especially injuries to oﬀspring and potential oﬀspring. However, excluding women from
clinical trials also bears the risk of liability for pharmaceutical manufacturers and, indirectly, for physi-
cians.101 Manufacturers’ liability results when, after a drug is on the market, evidence emerges that the
drug is more dangerous or less eﬀective in women. For example, a woman may have an adverse reaction
to one of her prescriptions and discover that the drug was never tested in women; the woman’s exclusion
from clinical research caused the injury. Under strict liability principles, manufacturers may be held liable
for the defective design of a product, and a drug that has not been adequately tested may be found to be
defectively designed. In addition, manufacturers must warn about not only the known risks of a treatment
but also foreseeable risks that should have been known. The duty to warn about foreseeable risks requires
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37that pharmaceutical manufacturers apply state-of-the-art testing methods to their products. With the re-
cent discovery and understanding of physiological diﬀerences between men and women with regard to drug
eﬃcacy, dosing, and adverse reactions, it would be diﬃcult to argue that all-male studies of drugs that may
be used by women represent state-of-the-art testing methods. Also, if the court ﬁnds that the manufacturer
deliberately avoided learning about whether a risk was associated with its drug, the manufacturer could be
liable for punitive damages. Case law suggests that if a drug was found to cause injuries to women but
women were excluded from clinical trials of the drug, the pharmaceutical manufacturer might be held liable
for failing to test the drug in women.102
For physicians, liability resulting from exclusion of women from drug trials arises in the form of negligent
drug prescription. For example, the physician could be liable for either prescribing a drug to a woman for a
diﬀerent purpose than that for which it was initially designed and tested or for prescribing a drug in disregard
of the drug’s label that it has not been tested in women.103 Thus, while it may seem less time-consuming
and less expensive to investigators to exclude women from clinical studies, in the long run it may be much
more expensive to pay for the clinical consequences of not knowing about gender-related diﬀerences in drug
eﬀects.
B. Rationales for Excluding Women of Childbearing Potential
Despite the fact that the FDA has lifted its 1977 guideline on the exclusion of women of childbearing potential
from clinical trials, there remain valid concerns about including this subgroup in human subject research,
concerns that go beyond the protectionist policy previously rejected as overly paternalistic. Arguments in
102Id. at 95.
103Id.
38favor of excluding women from clinical trials include the risk to potential children and the potential for legal
liability, problems with recruitment and retention of participants and the increased cost of including women,
the negative eﬀect that including women may have on women’s health care, and the fact that diﬀerences in
drug response or drug disposition due to gender are not clinically signiﬁcant.
1. Risk to Potential Children and Legal Liability
Protecting fetuses and the future reproductive capacity of women with childbearing potential remains a
concern for those involved in clinical research and trials. This concern is reﬂected in the FDA’s 1993 guideline
by the FDA itself when it stresses the need, where appropriate, for women of childbearing potential to use
contraception or abstinence while participating in early trials and sometimes beyond the completion of the
study, and the use of pregnancy tests before exposure to the drug. The inclusion of these directives in the
guideline indicates lingering concern about the safety of including women of childbearing potential in clinical
drug trials. Those in favor of excluding women of childbearing potential from clinical trials argue that
potential fetuses and the reproductive capacity of women must be protected by excluding women because
possible children cannot consent to their inclusion in clinical studies; consent policies created to protect
research subjects do not adequately protect potential fetuses since it is the mother, rather than the child,
that consents.104 In addition, the interests of later generations should be protected by earlier ones. Finally,
biologically mediated risks to future human beings are uniquely unacceptable. There is something inherently
worse about biologically mediated risks as compared to other risks that social action creates for future human
104J.D. Moreno. 1994. “Ethical Issues Related to the Inclusion of Women of Childbearing Age in Clinical Trials.” In: Women
and Health Research: Ethical and Legal Issues of Including Women in Clinical Studies, Volume 2. Anna C. Mastroianni, Ruth
Faden, and Daniel Federman, eds. (Washington, D.C.: National Academy Press, 1994).
39generations.105
Concerns about potential fetuses and the reproductive capacity of women of childbearing potential are
compounded by the fear of legal liability if a women suspects that damage to a fetus or gamete was due to
participation in a study.106 The threat of liability exists for injury to any subject of clinical research, but the
greatest concern about liability is the possibility of injury to oﬀspring resulting from the mother’s exposure
either before or after conception due to several factors. First, fear of liability continues to be inspired
by the experiences of thalidomide and DES making researchers particularly wary of including women of
childbearing potential in early phase drug studies when the eﬀects on both adult and oﬀspring are largely
unknown. Second, although it may be diﬃcult for a plaintiﬀ to prove causation, the magnitude of harm
that could be alleged to result from in utero exposure to a drug is great. Third, the statute of limitations is
usually longer for cases of injury to children, and damage that occurs in utero may not show up until years
later, leaving potential defendants liable for an indeterminate amount of time. Finally, legal actions can be
extremely costly to defend, even if the plaintiﬀ’s case is weak and the question of liability is uncertain, and
researchers and drug companies prefer to take action that appears likely to eliminate or reduce the risk of
becoming involved in litigation.107 Although the reported incidences of research-related injuries generally
appears to be quite low, fear of liability continues to make researchers apprehensive about including women
of childbearing potential in clinical studies.
2. Recruitment and Retention Issues and Increased Cost
105Id. at 30.
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40In addition, including women in clinical trials involves several issues relating to recruitment and retention
of study participants.108 Investigators who wish to recruit and retain women in their studies may encounter
problems related to feasibility, logistics, and cost. The NIH Revitalization Act speciﬁcally discounts the
issue of cost in its requirement that investigators increase the representation of women in their studies,
but as a practical issue, the expense of including women in research may limit the extent to which equity
in research can be achieved and may prompt more investigators to seek exemptions from requirements of
inclusion. The feasibility of recruiting and retaining participants for clinical studies depends on the number
of women in the reference population and their characteristics in relation to the study. If eligible women are
rare relative to men, or if eligible women in an ethnic, socioeconomic, or age group of interest are relatively
rare in comparison with aﬄuent young white women, special eﬀorts will be needed to identify and attract
these subjects. The feasibility of studying women is also aﬀected by social conditions that may limit the
personal autonomy of women. Women may have less ﬂexibility than men in terms of lifestyle or keeping
appointments during work hours. Personal safety may also be a greater concern with respect to evening
appointments, which would require the provision of transportation, security guards, and the like. Arranging
child care during clinic appointments may be more of a problem when studying women than when dealing
with men.109
Known variations in hormonal status that aﬀect the results of laboratory tests and inference about treatments
makes conducting studies that include women more time-consuming and labor-intensive.110 For situations
in which menstrual cycle variation or other reproductive variables are related to the issues under study, the
feasibility of the study will depend on the ability to schedule or plan around this variability. Finding enough
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41women with the right reproductive or hormonal status and then scheduling around this variability takes time
and eﬀort and thus may also increase recruitment costs. Recruiting these women and scheduling around
their hormonal variations may also increase sample sizes in order to balance reproductive or hormonal status
within the study population. Further, the factors that motivate women to participate in clinical studies,
particularly women from diﬀerent racial and ethnic groups, the elderly, and the poor, may be diﬀerent from
those that apply to men. Similarly, the modes of inﬂuence through which women are persuaded to enter
and remain in clinical studies may also be culture- or gender-speciﬁc.111 Including women in clinical trials
may therefore require investigators to develop and implement gender-speciﬁc recruitment programs, which
may in turn require special staﬃng (for example, elderly women to recruit elderly women into studies) and
the costly creation of both new recruitment strategies and the duplication of certain aspects of existing
recruitment practices for women as a separate subgroup, and for diﬀerent racial and ethnic groups within
this subgroup. Finally, decisions regarding the appropriateness of individual participation in clinical studies
can be inﬂuenced by a communal perception of risk and beneﬁt, leading to motivation or resistance to
participate based in part on group or community membership.112 For example, African American women
may resist participating in research based on stories of covert sterilizations in the past or the exploitation of
African American men in the Tuskegee study. Surmounting these community perceptions in order to recruit
and retain women may be extremely diﬃcult.
3. Negative Impact on Women’s Health
111Id.
112Id. at 121.
42Policies designed to ensure the inclusion of women in clinical trials of treatment eﬃcacy may be applied
so uncritically as to hamper rather than enhance the advancement of scientiﬁc information about these
groups.113 The detection of signiﬁcant diﬀerences among relevant subgroups generally requires clinical trials
that are prohibitively large, time consuming, and expensive. It has been suggested, for example, that the
cost of clinical drug development could double if parallel trials are conducted among men and women.114
Medical researchers may be caught between limited resources and their goal of answering many pressing
medical questions. As a result, they may have to sacriﬁce statistical power in order to allow for complete
representation of the subgroups of interest.
4. Gender Diﬀerences in Drug Response Are Not Signiﬁcant
Finally, those in favor of excluding women from clinical trials posit two somewhat conﬂicting and paradox-
ical arguments. First, they argue that biologic diﬀerences between men and women may reﬂect genetic,
physiologic, lifestyle, cultural and social diﬀerences, yet the mechanisms that explain these diﬀerences are
unknown.115 Without ﬁrst understanding how these diﬀerences are created, it is diﬃcult for investigators
to isolate the eﬀects of drugs on subjects when they include both men and women in their research. At
the same time, it is argued that diﬀerences in drug disposition or drug response due to gender are actually
not clinically signiﬁcant and thus women need not be studied as a special subgroup.116 This argument is
based on intersubject and intrasubject variability which patients exhibit in both the pharmacokinetics and
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43pharmacodynamics of drugs. Most drugs on the market today exhibit a wide therapeutic index; major
diﬀerences exist between the doses, blood concentration, or receptor concentration necessary to achieve a
positive therapeutic response versus those amounts that elicit a toxic response. Even if these drugs are only
tested in men, there is enough intersubject variability inherent in the male population that the diﬀerences
between the male and female patient populations are already encompassed by the variability within the male
population. Thus, excluding women from clinical trials of drugs with wide therapeutic indexes will not have
negative health consequences for women.
Other drugs critical to health care exhibit a narrow therapeutic index; small changes in dose or concentration
can shift a patient from an eﬃcacious state to a toxic condition or a state where no eﬃcacy is exhibited.
While many drugs exhibit substantial intrasubject and intersubject variability, all narrow therapeutic index
drugs, by deﬁnition, must exhibit low intrasubject variability. If this were not so, a patient maintained on
a particular dose would experience cycles of eﬃcacy, lack of eﬃcacy, and toxicity during a constant dosage
regimen. In fact, if a narrow therapeutic index drug does exhibit high intrasubject variability, it will not
pass Phase II testing during the drug development process, since it would be impossible to show eﬃcacy for
a particular dose. However, narrow therapeutic index drugs may, and often do, exhibit marked interpatient
variability. As a result, these drugs are titrated in the patient by the clinician to the appropriate dose or
concentration. Thus, it is immaterial whether women diﬀer signiﬁcantly from men in their pharmacokinetics
and/or pharmacodynamics since in every case the drug must be individually titrated; excluding women from
clinical studies for narrow therapeutic index drugs will not have negative health consequences for women
because of this individualized process.117
PART III: Empirical Evidence of Exclusion and Inclusion
117Id. at 42.
44The historical evolution of policies and regulations concerning the participation of women in clinical trials
and the arguments and rationales for and against including women of childbearing potential in clinical trials
must be considered alongside the available evidence concerning whether women have participated in the
whole of clinical studies to the same extent as men, and whether women have been disadvantaged by policies
and practices regarding their participation or by a failure to focus on their health interests in the conduct
of research. Unfortunately, despite the growing literature on women and biomedical research, attempts to
determine women’s participation in trials and the consequences of previous and currently existing policies
and regulations have been hindered by a scarcity of reported data.118 The sources of information available
vary widely in scope and method, and while all provide some kind of data on women’s participation in
clinical studies, many do not provide the kinds of information necessary to make a judgment about the
appropriateness of the reported study composition (for example, condition under study, percentages of male
and female subjects included in studies of conditions aﬀecting both males and females, adequacy of sample
size to analyze gender diﬀerences). In addition, much of the available evidence may be colored by the
publishing preferences of both authors and editors.
The ﬁndings and conclusions of research on women’s participation in clinical studies conducted between 1977
and 1993 are insuﬃcient to allow for any deﬁnitive conclusion as to whether women in the past have been
systematically excluded from or underrepresented in clinical trials to their detriment. Some studies found
that an appropriate number of women were included in speciﬁc study populations and that more female-only
than male-only studies were being conducted. Others found that women were over- or underrepresented in
certain types of studies. Still others found that women – especially the elderly and poor women – were less
likely to be included in studies than men.119 Based on these studies it is impossible to conclude that women
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45have or have not actually participated in clinical research. The Appendix summarizes the ﬁndings of the
studies conducted between 1977 and 1993 on women’s participation in clinical trials.
Although it cannot be established that gender inequity existed in the whole of past clinical research, there is
evidence that women have been excluded or included in numbers too small to yield meaningful information
about their treatment in the areas of AIDS and heart disease research. In both of these areas, there
is clear evidence that women have either been excluded altogether or included in numbers too small to
yield meaningful information about their treatment. Several well-known studies of cardiovascular disease
have not included any female participants. These include the MRFIT, the Coronary Drug Project (CDP),
Lipid Research Clinic, and the Physicians’ Health Study, all of which have had widespread inﬂuence on
the treatment and prevention of heart disease. MRFIT (1977) was a study of 12,866 men between the
ages of 35 and 57, designed to assess the eﬃcacy of intervention for individuals at high risk for coronary
heart disease because of elevated serum lipids, hypertension, and cigarette smoking. CDP (1986) was a
randomized, controlled clinical trial designed to evaluate the eﬃcacy of several diﬀerent lipid-inﬂuencing
drugs in prolonging the lives of men with a prior history of myocardial infarction. The Physicians’ Health
Study (1989) was a randomized controlled trial of 22,071 male physicians designed to determine whether
low-dose aspirin therapy decreases the risk of myocardial infarction and whether beta-carotene reduces the
risk of cancer. Because these studies did not include women, they could not produce deﬁnitive information
about prevention and treatment of heart disease in women. The extrapolation to women of the male-
generated ﬁndings of MRFIT, CDP, and PHS is faulty because it ignores the importance of estrogen in
women as an antiatherogenic agent and because the natural history of coronary heart disease is diﬀerent in
men and women.120 Further, such gender-exclusive research reinforces the myth that cardiovascular disease
is a uniquely male disease when in fact cardiovascular disease is the leading cause of death for both men and
120Id. at 64.
46women.121
Studies show that women have also been underrepresented in AIDS research.122 Despite the fact that the
ﬁrst cases of AIDS in women were reported in 1981 and the number of these cases has been increasing
rapidly since 1986, it was only in 1994 that comprehensive studies looking at the epidemiology of the disease
in women began to be conducted. In clinical trials of AIDS drugs, which often provide signiﬁcant sources of
ﬁrst-rate medical care and access to experimental treatments for persons with AIDS, the number of women
participating has lagged behind expectations for a disease that is increasing rapidly among women. More
importantly, where women have been the focus of clinical research, the primary research question has been
how to reduce or prevent a vertical transmission of human immunodeﬁciency virus (HIV) from a pregnant
woman to a fetus or newborn, not how to treat the female-speciﬁc manifestations of HIV diseases. Further,
until recently, there has been almost no research explaining the mechanisms of male-to-female transmission
of HIV and little research directed at the development of antiviricidal preparations that could be used by
women to reduce their chances of contracting the infection through sexual activity.
Conversely, the most recent studies I was able to locate on women’s participation in clinical research indicate
that women are participating in clinical trials equally with men. The Center for Drug Evaluation and
Research (CDER) conducted a retrospective review of clinical trial protocols and labeling for 185 new
molecular entities approved by CDER between January 1, 1995 and December 31, 1999.123Enrollment data
were derived from medical oﬃcers’ reviews and tabulated according to gender, while approved product
labeling was searched for statements related to product use in humans. Speciﬁcally, the study found that
overall, women appear to participate in clinical trials at nearly the same rate as men even when gender-speciﬁc
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47products are excluded. A total of 493,600 individuals were described in the medical oﬃcers’ reviews as being
enrolled in the 2,581 clinical trials for all products examined in the study. Gender could be determined from
the medical oﬃcers’ reviews for seventy-four percent of the participants; of these, forty-nine percent were
female and ﬁfty-one percent were male When gender-speciﬁc products such as those for ovarian or breast
cancer were excluded from analysis, forty-eight percent of participants in clinical trials were female and 52
percent were male. Some diﬀerences in participation were found from year-to-year; women appeared to be
represented least in 1995 and most in 1996. However, when they evaluated only those participants for whom
gender could be determined and eliminated those enrolled in gender-speciﬁc products, the authors found
women comprised forty-two percent of participants in 1995, ﬁfty-one percent in 1996, forty-four percent in
1997, ﬁfty-ﬁve percent in 1998 and forty-four percent in 1999. The study also found that of the 185 product
labels reviewed, sixty-eight percent contained some statement related to gender, twenty-seven percent of
which indicated that there was no diﬀerence between the genders, and twenty-two percent of which described
actual gender diﬀerences. Of the products for which labeling described gender eﬀects, none required a change
in the dosage based on gender diﬀerences. The authors of the study concluded that women are participating
in clinical trials of new drugs in approximate proportion to their representation in the population and that
the majority of product labeling contains references to gender evaluation.
A study by Meinert, Gilpin, Unlap, and Dawson looked at clinical trials published between 1966 and 1998 in
U.S. journals and indexed in MEDLINE.124 In 1998, sixty-ﬁve percent of the 8,903 trials identiﬁed involved
males and females, ten percent involved males only, 11 percent involved females only, and the remaining
fourteen percent could not be classiﬁed as to gender mix. The study found that the majority (sixty-four
percent) of heart trials involved both men and women and that diﬀerences seen for heart disease and HIV
trials are in directions consistent with male-female disease burden. In the case of neoplasms, female-only
124C.L. Meinert, A.K. Gilpin, A. Unalp, and C. Dawson, C. 2000. “Gender Representation in Trials,” Controlled Clinical
Trials 21: 462-475.
48trials outnumbered male-only trials 2.56 to 1, increasing to 3.16 to 1 when breast and prostate trials were
removed. The authors concluded that, overall, there was little support for the perception that women have
been underrepresented or understudied in trials or that there is an eﬀort bias in favor of men. The authors also
argue that as far back as 1979, evidence was against the perception that women were being underrepresented
and understudied. They note that of the 986 trials listed as ongoing in NIH’s 1979 inventory of clinical trials,
eighty-one percent involved both males and females, and that among the remaining trials, there were more
female-only than male-only trials. Finally, the authors believe that changes in the gender mix of trials cannot
be attributed to the policy and regulatory changes of the 1980s and 1990s because the biggest change in
the mix of published reports occurred prior to those events; the ratio of female-only to male only trials
jumped from 0.53 for the decade 1966-1975 to 0.89 for the following decade. Thus, not only is the evidence
regarding the actual participation of women of childbearing potential in clinical trials inconclusive, but the
reasons for changes in women’s participation, according to these authors, is also not clearly understood or
fully explained by policy changes over time.
PART IV: Analysis of Regulations, Policy, and Rationales
The arguments and rationales for and against including women of childbearing potential in clinical trials
indicate that there is no simple answer to the question, “Should women participate?” Rather, the previous
discussion indicates that the answer to this question involves considering a multitude of legal, ethical, and
physiological issues against a backdrop of policies and regulations. The answer to this question is made
more complex when the cost of subgroup analysis is taken into consideration. The issue of participation
is muddled further due to popular opinion which inﬂuences policy and regulation, opinion which may exist
independently of any actual facts about women’s participation in research and women’s health in general.
The current regulatory system does not require the FDA to include women in clinical drug trials. Despite
49the fact that the NIH Revitalization Act and the FDA’s 1993 guideline require and encourage respectively
the inclusion of women in clinical drug trials, neither of these provisions carries the force of law for the FDA.
However, a regulation legally requiring the FDA to include women in clinical research does not seem to be
necessary at this time. As noted by the FDAMA Women and Minorities Working Group, current regulations
and policies seem to ensure that women are suﬃciently included in clinical trials. Federal law requires the
analysis of eﬀectiveness and safety data for women in NDA applications, and this law is supported by an
FDA guideline; the clinical hold rule allows the FDA to place a clinical hold on studies that exclude women;
and an FDA guideline emphasizes the importance of including women and evaluating drug eﬀectiveness in
this subgroup. These regulations and policies are strengthened by the NIH Revitalization Act which allows
NIH to deny funding to studies that exclude women.
Taken together, these regulations and policies appear to ensure that women are included in clinical trials.
In addition, although the NIH Revitalization Act requires the inclusion of women while the FDAMA does
not, these two regulations are not contradictory. Rather, these regulations are harmonized by the fact that
the FDAMA requires the participation of women to be studied in eﬀect to determine whether the FDA
itself needs a rule analogous to the NIH Revitalization Act and applying directly to FDA trials. If it is
determined under the FDAMA that no further guidance is needed, as it was in 1998, the NIH Revitalization
Act serves as a check against this ﬁnding, ensuring that women are in fact being included, at least in the
trials NIH funds or sponsors. The NIH Revitalization Act does provide wide latitude for exemption from
the requirement that women must be included in NIH-funded trials. Nonetheless, according to empirical
evidence, it does not appear that women are in fact being widely excluded or understudied in clinical drug
trials, indicating that exemptions are not being widely sought by investigators or widely granted by NIH. If
women are in reality suﬃciently participating in clinical trials, then the FDAMA seems like an eﬀective reg-
50ulation. Though it requires neither inclusion nor exclusion, it ensures that the issue of women’s participation
in clinical trials will be periodically considered and that guidance will be issued as needed. This means that
if studies conclusively reveal that women, in the future, are being excluded from trials, steps may be taken
to remedy the situation.
Thus, the current regulatory system, supported by federal policy, seems to support and promote the inclu-
sion of women in clinical trials and the results of studies indicate that women are in fact being included.
The weight of scientiﬁc evidence supports the inclusion of both genders; the diﬀerences in drug eﬀects and
responses due to gender diﬀerences is persuasive evidence that for their results to be generalizable to women,
drug trials must include women. The fact that most treatments do not diﬀer signiﬁcantly in their eﬀect by
gender reinforces the justiﬁcations for a principle of inclusion: if most treatment eﬀects in clinical trials do
not diﬀer by gender, it is reasonable to include both genders.
At the same time, while current policy supports the inclusion of women and including women in clinical trials
seems both beneﬁcial and necessary due to the diﬀerences between men and women, the question remains
– “At what cost?” Where there are no anticipated eﬀects by gender, a policy that requires investigators
to include suﬃcient representation of both genders to permit subgroup analyses would require that clinical
trials signiﬁcantly increase their size and proportionately increase their expenses. Regardless of the fact that
the FDAMA does not require inclusion, the NIH Revitalization Act requires investigators to both justify
any gender or racial exclusions and identify and analyze any gender diﬀerences. Even when there are no
anticipated eﬀects by gender, women currently must be included unless there is substantial scientiﬁc data
demonstrating that there are no signiﬁcant diﬀerences between the eﬀects of the intervention or variable
under study on this group and the eﬀects on the subjects included in the trial. The Act also speciﬁes that
cost is not a valid reason to exclude a subgroup or fail to analyze gender diﬀerences. The analysis of gender
diﬀerences is also supported by the FDA’s 1993 guideline; women must not only be included, but subgroup
51diﬀerences must also be studied. The goals of this Act and the guideline are laudable; investigators should
be obligated to be inclusive in their recruitment practices and to justify any departures in the composition
of the study population from what might be expected given the characteristics of the problem under inves-
tigation. However, there remains a concern that if the Act is interpreted too rigidly, it will make costly and
undue demands on the scientiﬁc research process and impede the implementation of its noble goal. Clini-
cal trials should include both genders but requiring investigators to enroll suﬃcient numbers to ensure the
statistical power needed to detect unsuspected and implausible gender diﬀerences produces little additional
information at greatly increased cost. It does not seem that the interests of equity in health research are
best served by requiring that every clinical trial be large enough to conduct valid analyses of every relevant
subgroup diﬀerence, as current policy appears to dictate. The added cost of such analyses may jeopardize
the long-term goals of improving scientiﬁc knowledge and understanding the health problems of all peoples.
Strategies other than clinical trials exist to help devise hypotheses about the diﬀerential response of men and
women to medical intervention. These strategies may be signiﬁcantly less costly than large-scale clinical trials
that include signiﬁcant numbers of men and women to detect gender diﬀerences in response. Meta-analysis,
a set of quantitative techniques for combining data from diﬀerent studies of the same or similar phenomena,
is one such strategy that is inherently inexpensive and particularly useful for detecting subtle associations
between interventions and outcomes and between demographic characteristics and drug eﬀects.125 Meta-
analysis can be used by clinical investigators to detect signiﬁcant diﬀerences between treatment and control
groups where sample sizes in individual studies were too small to allow the detection of statistically signiﬁ-
cant eﬀects. At the same time, meta-analysis may indicate through averaging that an eﬀect that appeared
to be signiﬁcant in one study is actually less signiﬁcant. Meta-analysis also allows investigators to detect
contradictions or discrepancies among groups of studies. With a collection of studies in a particular area of
125Women and Health Research: Ethical and Legal Issues of Including Women in Clinical Studies, Volume 1, supra note 1
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52research, investigators can compare subgroups of studies with divergent ﬁndings to detect mediating factors
of study design, treatment, context, measurement, or analysis that otherwise might not have appeared note-
worthy.
Outcomes research, which involves the systematic study of health impact of an intervention, and speciﬁcally
pharmacoepidemipologic research, a type of outcomes research designed speciﬁcally for the study of drug
eﬀects in user populations, is another inexpensive and useful alternative to clinical trials.126 The pharma-
ceutical industry has recently placed renewed emphasis on the use of these nonexperimental, observational,
epidemiologic techniques. Postmarketing surveillance is one of several pharmacoepidemiologic techniques
used to study the eﬀects of drugs in uncontrolled settings and in larger numbers of people than can be
included in the drug development process. Pharmacoepidemiologic studies avoid some of the important
shortcomings of clinical trials, speciﬁcally the introduction of intervention and observation eﬀects, and the
exclusion of eﬀects resulting from the usage of concomitant medications, presence of other illnesses, and lack
of patient compliance. Developments in computer technology and health care management have yielded
large, automated, multipurpose databases of patient information collected by health maintenance organiza-
tions, an important resource for pharmacoepidemiology. Such large databases permit the epidemiologist to
collect information on all drug exposures and all major medical outcomes and to take into account major
stratifying variables. Where calculated rates of adverse eﬀects among users tend to be unreliable, a struc-
tured epidemiologic study can be a powerful tool for qualitatively assessing unexpected adverse events.
Finally, the pharmaceutical industry has also begun using new techniques designed to expedite and enhance
the results of drug development. Pharmacokinetic screens, one of these techniques which may be useful in
detecting diﬀerential responses to drugs between men and women as well as other subgroup diﬀerences, can
be used during drug development to infer the inﬂuence of demographic factors such as age and gender on
126Id. at 102.
53the pharmacokinetics of a drug (the drug’s absorption, distribution, and metabolism in the body, and the
drug’s excretion from the body) and to suggest the likelihood that a drug-drug or drug-disease interaction
will occur.127 The screening process involves the analysis of drug levels in members of speciﬁc subgroups at
designated points throughout a Phase III trial. Conducting a pharmacokinetic screen during drug develop-
ment adds little extra cost to the development process because the necessary data is collected from patients
already participating in clinical trials.
These promising strategies may help to dissipate some of the controversy inspired by including women in
clinical drug trials and requiring subgroup analysis of gender diﬀerences by better balancing the need to
study women’s health against the cost of such research. More importantly, these strategies can identify
gender diﬀerences in drug eﬀects and response without requiring that every clinical trial include women
and analyze subgroup diﬀerences. Because it appears that women are in fact participating in clinical trials,
requiring their inclusion seems to be an unnecessary and harmful move particularly in light of the fact that
alternative methods for understanding gender diﬀerences exist.
127Id. at 103.
54CONCLUSION
Historically women of childbearing potential have been considered a vulnerable population and therefore
systematically excluded from clinical trials. As a result, there is a general perception that biomedical research
has not given the same attention to the health problems of women that it has given to those of men, and
that women may not have beneﬁted from advances in medical diagnosis and therapy because of their lower
rates of participation in clinical studies. These perceived inequities have been the focus of public attention
and legislative action over the last two decades as women’s health advocates and others have challenged the
content of the national research agenda.
The historical exclusion of women from clinical drug trials resulted in a scientiﬁc paradigm premised on a
male norm – the tendency to conceive of men gender neutrally and to perceive their identity and experience
as the characterization or standard of what it is to be a person and to portray female diﬀerences, where they
occur, as deviant.128 According to this norm, basic biological diﬀerences between the sexes are irrelevant
for most scientiﬁc research; male-only studies are regarded as the scientiﬁc ideal for conducting research in
order to ensure homogeneity across the groups being compared; and male physiology becomes the implicit
normal standard for judging etiology, physiology, and response to intervention. Female physiology is ex-
amined only to the extent that it is supposed to deviate from the male norm. Until the end of the 1980s,
little attention was given to sex and gender as valuable and signiﬁcant variables to be studied in biomedical
research, indicating the continued presence of the male norm. In the past decade however, the issue has
128J.A. Sechzer, A. Griﬃn, S.M. Pfaﬄin. 1994. “Women’s Health and Paradigm Change.” In: Forging a Women’s Health
Research Agenda: Policy Issues for the 1990s (Jeri A. Sechzer, Anne Griﬃn, and Sheila M. Pfaﬄin, eds., 1994).
55clearly attracted the attention of the public, government agencies, and the scientiﬁc community, and has
resulted in new policies and regulations focused on including women in clinical research. Nonetheless, the
perception that scientiﬁc research is still based on a male norm prevails.129
Perception is often times more important than fact, regardless of whether it is right or wrong. The chasm
between perception and truth would not be important if not for the fact that perception frequently drives
the actions we take and may have serious consequences. In the case of clinical research, and clinical trials in
particular, the perception that publicly funded research favors one gender over the other has driven policy
and regulations for the past several decades. These policies and regulations currently reﬂect a shift away from
the male norm paradigm and toward a paradigm that conceives of men and women as diﬀerent yet equally
important participants in clinical research. Aligning popular perception with this new paradigm is extremely
diﬃcult, yet at the same time crucial to ensuring that clinical research continues to progress eﬃciently and
eﬀectively. In cases of major policy change, the impetus for such change usually comes from organizations
outside the government. Nongovernmental actors thus play a primary role in the creation of public policy.
If these actors inﬂuence policy and regulatory change and these actors continue to perceive that clinical
research favors men, they will support and potentially achieve rigid interpretation of current inclusion and
subgroup analysis requirements and may even succeed in establishing more stringent requirements, with the
ultimate eﬀect of making this type of research prohibitively expensive and time-consuming.
The studies discussed in Part III in general and the conclusions of the 1998 Meinert et al. study, in par-
ticular, may indicate that while public perception drives policy and regulatory change, there may be no
real correlation between regulations and policies and women’s participation in clinical trials. Although it is
unclear how reliable these studies actually are, as bias may be prevalent, the studies do not oﬀer results that
would seem to reﬂect the regulatory system at the time the studies were conducted. For example, Meinert’s
129J.W. Scott. 1993. “How Did the Male Become the Normative Standard for Clinical Drug Trials?,” Food and Drug Law
Journal 48(2): 187-93.
56study found that in 1979, when the FDA’s guideline encouraged the exclusion of women of childbearing
potential from clinical trials, nearly 81 percent of NIH trials included women; Kinney’s 1981 study of 50
clinical trials reported in 1979 revealed that young women served less frequently than young men as subjects
in premarketing clinical drug trials, but women were not in fact completely excluded.130 The participation
of women in trials does not necessarily mirror the regulatory system.
It seems possible that the popular perception that women have been excluded from clinical trials in the past
and continue to be excluded currently, compounded by the historic use of the male norm in clinical research,
prompted the emergence of policy and regulations preferring inclusion, despite the fact that the empirical
evidence may not indicate that women have been excluded from health research to their detriment. If women
are in fact being included in research, this must be publicized in order to prevent nongovernmental actors
from advocating and possibly achieving more stringent inclusion requirements and potentially jeopardizing
important scientiﬁc research. Thus, it seems that changing the perception that women are being neglected by
clinical research to their detriment, rather than changing the existing policy and regulatory system regarding
their inclusion in clinical trials, is the area currently most in need of reform. This type of change would
ensure that women participate in clinical trials but that such participation would not be so rigidly enforced
as to make clinical research prohibitively expensive.
How this perception can be changed is more diﬃcult to formulate. The NIH Revitalization Act of 1993
is one step in this direction. The Act enhances the availability of information about women’s participa-
tion in clinical studies by requiring the directors of NIH, the Oﬃce of Research on Women’s Health, and
the National Library of Medicine to collaborate in establishing a “data system for the collection, storage,
analysis, retrieval and dissemination of information regarding research on women’s health that is conducted
or supported by the national research institutes.”131 The Act also requires that the data system include
130E.L. Kinney, J. Trautman, J.A. Gold, E.S. Vessel, and R. Zelis. 1981. “Underrepresentation of Women in New Drug Trials,”
Annals of Internal Medicine 95(4): 495-499.
131NIH Revitalization Act of 1993, supra note 48.
57a registry of clinical trials of experimental treatments that have been developed for research on women’s
health, as well as information about subject eligibility criteria, gender, race, ethnicity, age, and the location
of the trial. These strategies, however, must be supplemented by better eﬀorts to recruit women into clinical
trials. Only by encouraging the subgroup that tends to perpetuate the perception of exclusion to participate
in clinical trials will the perception actually change. Women are in fact participating but it seems likely
that this is not widely known. Thus, by more actively and publicly recruiting women into clinical trials, the
scientiﬁc research establishment will convey to women that their participation is essential to clinical research
and that women are not in fact being excluded to their detriment.
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59Kinney et al., 1981 50 clinical trials
reported in 1979
Young women served
less frequently than
young men as subjects
in premarketing clinical
drug trials. Women are
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new drug trials
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61Hooper, 1990 Women enrolled in 5
categories of
randomized-control
trial
Women appear to be
included in trials of AIDS
drugs in a proportion that
approximates the
proportion of people with
AIDS who are women.
Women appear to be
slightly overrepresented in
trials of nicotine gum for
smoking cessation.
Women appear to be
underrepresented in
clinical studies of
antiplatelet drugs for
preventing smoking,
antihypertensives, and
drugs for myocardial
infarction.
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cent
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63Cotton, 1990 Multiple Risk Factor
Intervention Trials
(MRFIT), Physicians
Health Study, all large
trials of
cholesterol-lowering
drugs that include men
only
There are important gaps
in knowledge about the
medical treatment of
women, the elderly, and
nonwhite persons despite
mounting documentation
of diﬀerences in drug
responses and risk proﬁles
among these cohorts.
Edwards, 1991 Questionnaire sent to
46 of the largest
pharmaceutical
companies
All 33 respondents
reported that they collect
data on gender of trial
participants and 25 of the
33 reported that they
deliberately recruit
representative numbers of
women for clinical trials.
Study Author Coverage Findings and Author’s
Conclusion
IOM, 1991 907 grants Twelve percent of grants
represented research
including only women, 18
percent included only
men, 70 percent included
women and men. When
all grants were considered
together, women
comprised 53 percent of
the total study
population.
64PMA, 1991 Medicines in
development as of
December 1991
Noted 263 drugs were
under development for
use in women (to treat
diseases that aﬀect only
women, that
disproportionately aﬀect
women, or are one of the
top 10 causes of death in
women). Concluded that
America’s pharmaceutical
research companies
recognize the unique
medical needs of women
and are working hard to
resolve the diﬃculties of
developing drugs to meet
those needs.
Levey, 1991 Clinical trials reported
in all January issues of
Clinical Pharmacology
& Therapeutics
between 1981 and 1991
Comparing trials reported
in the 1981 and 1991
issues, found a decline in
the number of trials
restricted to male
subjects and a more than
twofold increase in the
number of trials that
included both men and
women, but comparing all
issues between 1981 and
1991, found no consistent
pattern.
Dresser, 1992 Select large-scale NIH
sponsored studies
The failure to include
women in clinical research
is ubiquitous.
Larson, 1994 Research protocols
approved by an IRB at
a major tertiary care
center during 1989 and
1990
Women were not
underrepresented in
clinical drug trials or
other types of research.
Age, race, and SES were
more likely than gender
to be associated with an
unjustiﬁed exclusion from
research protocols.
65Gannon et al., 1992 4,952 articles published
in sample years between
1970 and 1990 in the
areas of developmental,
physiological, and social
psychology
Signiﬁcant increases in
the number of female
authors and participants,
signiﬁcant decreases in
sexist language and
inappropriate
generalizations from
males to females, but
continued evidence of
discriminatory practices.
Gurwitz et al., 1992 All studies of speciﬁc
pharmacotherapies
employed in the
treatment of acute
myocardial infarction
that appeared in the
English-language
literature between
January 1960 and
September 1991
Age-based exclusions are
frequently used in clinical
trials of these
pharmacotherapies.
Because women outlive
men by an average of 7.5
years, they are
disproportionately
represented in clinical
trials.
PMA, 1992 91 clinical trials active
in October 1992 of
medicines for AIDS and
AIDS-related
conditions
Of the 91 medicines, 50
included women in human
clinical trials.
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68PMA, 1992 Orphan drugs under
development in October
1992
26 orphan products
were in development for
diseases that
predominantly or
exclusively aﬀect
women; for all trials of
orphan drugs,
enrollment of women
approximates the
prevalence in women of
the disease under study.
Women are adequately
represented in trials of
orphan drugs.
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Borins,
1993
160
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Medical
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se-
ri-
ously
gender-
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and
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ﬂawed.
Pham et al., 1992 AIDS Clinical Trial
Group (ACTG) clinical
trials
Women, intravenous drug
users, people of color, and
people of low income have
been grossly
underrepresented among
study subjects in ACTG
clinical trials.
69Charo,
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All
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70NOW Legal Defense
and Education Fund,
1993
ACTG clinical trials,
1990-1992
The percentage of female
enrollment in these trials
increased from 6.5 percent
to 7.8 percent between
1990 and 1992. The
numbers of women
enrolled in ACTG trials
are not enough to provide
sound and meaningful
data on the eﬀects of a
given drug in women.
Cotton et al., 1993 ACTG clinical trials,
1987-1990
Women accounted for 6.7
percent of ACTG clinical
trials between 1987 and
1990.
Study Author Coverage Findings and Author’s
Conclusion
Long, 1993 ACTG clinical trials, as
of January 1993
The percentage of women
accrued as ACTG trial
participants is slightly less
than women’s percentage
of CDC-reported AIDS
cases. Women seem to be
represented in ACTG
clinical trials in
proportion to the
incidence of AIDS among
women, but women have
been underrepresented in
trials of drugs for
AIDS-related
opportunistic infections.
Eichler et al., 1992 Selected 1988 issues of
the New England
Journal of Medicine,
Canadian Journal of
Surgery, American
Journal of Trauma, and
American Journal of
Psychiatry
Gender bias is pervasive
in medical research.
71Meinert, 1993 All (2,801) active
proposals, proposals
pending further IRB
action, and proposals
reviewed and completed
or terminated within
the last two years at
Johns Hopkins
University
181 protocols (6.5
percent) included only
males, 265 (9.5 percent)
include only females, and
2,355 (84 percent)
included both males and
females.
Meinert, 1993 293 trials listed in the
1979 NIH inventory of
clinical trials
All but 25 of the trials
included both males and
females, of those 25, 13
involved females and 12
involved males; all 12 of
the female-only trials
involved uniquely or
primarily female
conditions while only 4 of
the male-only trials
involved uniquely or
primarily male conditions.
Meinert, 1993 All papers (38)
published in the journal
Controlled Clinical
Trials since 1981 that
describe an actual
clinical trial
Only 28 provided explicit
statements regarding
gender inclusion criteria,
and of these 28, only 21
provided exact counts of
males and females. Of the
total number of subjects
in these 21 trials (78,840),
72,951 were males and
5,890 were females.
NIH, National Eye
Institute (NEI), 1993
Active NEI-supported
clinical trials
In almost all trials,
women comprise at least
40 percent of the
participants. Signiﬁcant
numbers of women are
included in a variety of
NEI-supported trials.
72Meinert, 1993 All (2,801) active
proposals, proposals
pending further IRB
action, and proposals
reviewed and completed
or terminated within
the last two years at
Johns Hopkins
University
A higher percentage of
male-only studies were
arbitrarily male-only
(75.2 percent) as opposed
to female-only studies
that were arbitrarily
female-only (21.2
percent).
NIH, NHLBI, 1993 All trials (49) under
way at NHLBI as of
May 1993
One trial was male-only, 8
trials were female-only,
and women’s inclusion in
the remaining 40 trials
ranged from 10 to 75
percent.
Study Author Coverage Findings and Author’s
Conclusion
Bird, 1994 All original articles
reporting results of
clinical studies in 1990
and 1992 issues of the
Journal of the
American Medical
Association
Found 207 of the 243
studies were related to
gender-neutral diseases,
and 49 percent of these
207 included between one-
and two-thirds women; of
the remaining 51 percent,
17 percent were
male-only, 6 percent were
female-only, 38 percent
had one-third or fewer
women and 14 percent
had one-third or fewer
men. Fifteen percent of
single-gender studies had
no apparent rationale for
their single-gender design.
Among those studies
examining gender-neutral
diseases, women were
more likely than men to
be underrepresented as
research subjects.
73NIH, National Cancer
Institute (NCI), 1993
NCI-supported clinical
trials active in 1992
Of 22,483 participants in
treatment trials, 12,490
were female and 9,993
were male; of 9,553
participants in prevention
trials, 4,727 were female
and 4,826 were male.
Murphy, 1993 ACTG clinical trials,
1992
As of August 1992,
females comprised 13.2
percent of the total
ACTG trial population.
For the 20 most recent
ACTG trials with
signiﬁcant enrollment,
women comprised 15.7
percent of the trial
population.
Korvick and Long, 1993 ACTG clinical trials,
1986, 1992
Representation of females
in ACTG clinical trials
increased from 2 percent
in 1986 to over 18 percent
in 1992.
74FDA, 1993 Phase I and Phase II
trials
11 new drug
applications pending in
1983
All drugs approved in
1988
The eﬀect of the 1977
FDA guideline regarding
the participation of
women of childbearing
potential in clinical
studies has been that
women have generally not
been included in Phase I
nontherapeutic studies or
in the earliest controlled
eﬀectiveness (Phase II)
studies.
Gender distribution of
study populations
generally approximated
condition incidence by
gender; males comprised
two-thirds of the study
population in studies of
cardiovascular drugs.
Gender distribution of
study populations
generally approximated
condition incidence by
gender; studies of two
cardiovascular drugs
included slightly more
men than women; 2 drugs
were studied more in
males for unclear reasons.
Study Author Coverage Findings and Author’s
Conclusion
75Schmucker and Vesell,
1993
All trials reported in
Clinical Pharmacology
and Therapeutics
(CP&T) during the
periods 1969-1971,
1979-1981, and
1989-1991, and in the
British Journal of
Clinical Pharmacology
(BJCP) during the
periods 1979-1981 and
1989-1991; all drugs
approved by the FDA
in 1981 and 1991 that
were listed in the 1991
Physician’s Desk
Reference (PDR)
The percentage of men-only
trials reported in CP&T
increased from 27 percent to
38 percent from 1969-1971
to 1989-1991; a similar
comparison in BJCP from
1979-1981 to 1989-1991
yielded a 5 percent increase.
In both journals during
these time periods, the
percentage of women-only
trials declined. Of 68
clinical trials published in
CP&T during 1991 that
included both men and
women, none claimed
diﬀerences in drug response
that were attributable to
gender; the majority of
trials failed to mention
whether or not the data
were analyzed for gender
diﬀerences. The 1992 PDR
revealed reservations
concerning use during
pregnancy, but not in
nonpregnant women, for
nearly all drugs approved
by FDA in 1981 and 1991.
Despite eﬀorts to rectify the
underrepresentation of
women as participants in
clinical trials, this practice
has continued during the
past decade. The absence in
the PDR of any
contraindications for use in
nonpregnant women are
diﬃcult to interpret because
they may reﬂect (1) no
evidence of gender
diﬀerences, (2) exclusion of
women from test
populations, or (3) failure
to analyze clinical trial data
for gender diﬀerences.
76Elks, 1993 Nongonadal clinical
studies reported in
single volumes of three
journals: Clinical
Pharmacology &
Therapeutics (CP&T)
(January through June
1992); American
Journal of Physiology:
Endocrinology and
Metabolism (AJP)
(July through
November 1992); and
Hypertension (January
through June 1992)
Of 49 studies reported in
CP&T, 14 included no
women and 2 included no
men. The remaining 26
studies had an average of 59
percent males. Of 32 studies
reported in AJP, 10
included only men, 1
included only women, and 4
gave no statement of the
gender of participants. The
16 remaining studies had an
average of 57 percent males.
Of 20 studies reported in
Hypertension, 8 included no
women and 3 were large
epidemiological studies with
equal representation. The 9
remaining studies had an
average of 64 percent men.
Frequent systematic
exclusion of females has
occurred; even in both-sex
studies, more men than
women are included than
would be likely by chance.
Zahm et al., 1994 Cancer epidemiological
studies published between
1971 and 1990 in
American Journal of
Epidemiology, American
Journal of Industrial
Medicine, Archives of
Environmental Health,
British Journal of
Industrial Medicine,
International Journal of
Epidemiology, Journal of
the National Cancer
Institute, Journal of
Occupational Medicine,
and Scandinavian Journal
of Work, Environment
and Health
Of a total of 1,233 studies,
562 (46 percent) include
only white men while the
remaining 671 studies
included subjects from
other race-gender groups.
Of these, 35 percent
included white women,
but only 14 percent
presented any analyses of
the women speciﬁcally.
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